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A vast majority of heart attacks occur due to rapid progression of plaque 
buildup in the coronary arteries that supply blood to the heart muscles. The 
diseased arteries can be treated with drugs delivered locally to vulnerable 
plaques—ones that may rupture and release emboli, resulting in the formation of 
thrombus, or blood clot that can cause blockage of the arterial lumen.  
In designing these local drug delivery devices, important issues regarding 
drug distribution and targeting need to be addressed to ensure device design 
optimization as physiological forces can cause the local concentration to be very 
different from mean drug tissue concentration estimated from in vitro experiments 
and animal studies. Therefore, the main objective of this work was to develop a 
computational tool-set to support the design of a catheter-based local drug 
 vii 
delivery system that uses nanoparticles as drug carriers by simulating drug 
transport and quantifying local drug distribution in coronary artery walls. Toward 
this end, a three dimensional mathematical model of coupled transport of drug 
and drug-encapsulated nanoparticles was developed and solved numerically by 
applying finite element based isogeometric analysis that uses NURBS-based 
techniques to describe the artery wall geometry.  
To gain insight into the parametric sensitivity of drug distribution, a study 
of the effect of Damkohler number and Peclet number was carried out. The tool 
was then applied to a three-dimensional idealized multilayered model of the 
coronary artery wall under healthy and diseased condition. Preliminary results 
indicated that use of realistic geometry is essential in creating physiological flow 
features and transport forces necessary for developing catheter-based drug 
delivery design procedures. Hence, simulations were run on a patient-specific 
coronary artery wall segment with a typical atherosclerotic plaque characterized 
by a lipid pool encased by a thin fibrous cap. Results show that plaque 
heterogeneity and artery wall inhomogeneity have a considerable effect on drug 
distribution.  
The computational tool-set developed was able to successfully capture 
trends observed in local drug delivery by incorporating a multitude of relevant 
physiological phenomena, and thus demonstrated its potential utility in optimizing 
drug design parameters including delivery location, nanoparticle surface 
properties and drug release rate. 
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Background and Significance 
This section provides a brief background on the concept of vulnerable 
plaque, its role in causing acute cardiac events and current status of medical 
therapy. For this, the structure adopted by Lau et al. in [1] and Spratt et al. in [2] 
will be followed closely while relying heavily on a few relevant articles [3-5] 
(along with the two previously mentioned articles) for content. After building the 
case for local drug delivery systems as a viable option for treating vulnerable 
plaques, the motivation for the proposed work will be presented by outlining 
potential application and significance of the computational tool developed.  
1.1 ACUTE CORONARY SYNDROME 
Cardiovascular disease is the number one killer in the United States. Each 
year about 1.1 million Americans suffer a myocardial infarction (MI), i.e., heart 
attack, and almost half of them die from it, accounting for 1 in 5 deaths in the 
United States [6, 7]. The majority of these cardiac events occur suddenly in 
patients with no known history of coronary artery disease. But a large number 
take place in patients already diagnosed and treated for cardiovascular diseases. 
Even with today’s best standard of care, one out of every six men diagnosed with 
a myocardial infarction will have another one within six years, while women are 
twice as likely to have a repeat MI [7]. Additionally, health care expenditure 
associated with cardiovascular diseases is increasing rapidly; in 2008 the 
 2 
projected cost was $448.5 billion [8]. There is, therefore, an overwhelming need 
to develop methods for early diagnosis and acute treatment of atherosclerosis—
the root cause of cardiovascular diseases, and prevent its progression to heart 
attack. 
 
Heart attacks are caused by blockages in the coronary arteries that supply 
oxygen-rich blood to the heart’s muscular wall (the myocardium). The obstruction 
in the arterial lumen retards the blood flow; as a result, the heart muscles starve 
for oxygen causing acute coronary syndrome. This condition manifests as either 
unstable angina (chest pain), or acute myocardial infarction (tissue death) that 




Figure 1.1: Coronary artery disease leading to acute coronary syndrome, causing 
heart attacks. [9] 
These blockages occur due to atherosclerosis—the build up of plaque in 
the arterial wall that develops from low-density lipoprotein cholesterol (LDL). As 
 3 
LDL enters the intima through the endothelium of the diseased artery wall, it 
reacts with oxygen producing oxidized-LDL. This triggers an immunoresponse 
where white blood cells, namely monocyte-derived macrophages are dispatched 
to consume the toxic oxidized-LDL forming foam cells—the main component of 
the atherosclerotic plaque. These lipid laden foam cells in turn capture monocytes 
that transform into macrophages, and the process repeats itself resulting in 
increased plaque size and gradual narrowing of the artery lumen (see Figure 1.2).  
 
 
Figure 1.2: Schematic figure illustrating the most common type of vulnerable 
plaque characterized by thin fibrous cap, extensive macrophage 
infiltration, paucity of smooth muscle cells, and large lipid core, 






Figure 1.3: Angiography is a poor predictor of vulnerable plaque. Here findings of 
four different papers are presented that reported the number of MI 
events and corresponding percent diameter stenosis. Majority of the 
MI’s occur in patients with less than 50% blockage. [10] 
1.2 VULNERABLE PLAQUE AND ITS IDENTIFICATION   
Patients with blockage of more than 60–70 percent are generally 
considered to be at a higher risk for acute myocardial infarctions (AMI). But 
recent studies using angiographic images show that a vast majority of these 
AMI’s occur in patients with less than 50 percent blockage (see Figure 1.3), 
indicating that factors other than degree of stenosis are responsible for these 
sudden cardiac events. Most acute coronary syndromes can be attributed to 
coronary thrombosis resulting from plaque rupture. Plaque disruption exposes its 











and blockage of the arterial lumen causing acute coronary syndrome. These 
plaques that are at high risk for rupture or erosion, are referred to as vulnerable 
plaques. 
Researchers have identified specific structural characteristics that 
distinguish vulnerable plaques from stable plaques, including, i) a large lipid-rich 
core (> 40% of plaque area), ii) a thin fibrous cap (< 165 µm), and iii) 
inflammation (see Figure 1.2). Figure 1.4 illustrates different types of vulnerable 
plaques based on their composition [5], providing a more comprehensive 
guideline for their identification. 
 
 
Figure 1.4: Different types of vulnerable plaque as underlying cause of acute 
coronary events and sudden cardiac death (SCD). A, Rupture-prone 
plaque with large lipid core and thin fibrous cap infiltrated by 
macrophages. B, Ruptured plaque with subocclusive thrombus and 
early organization. C, Erosion-prone plaque with proteoglycan 
matrix in a smooth muscle cell-rich plaque. D, Eroded plaque with 
subocclusive thrombus. E, Intraplaque hemorrhage secondary to 
leaking vasa vasorum. F, Calcific nodule protruding into the vessel 
lumen. G, Chronically stenotic plaque with severe calcification, old 
thrombus, and eccentric lumen. [5] 
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Additionally, systemic inflammation in vessel walls is known to be a 
reliable indicator of plaque instability. Therefore, detection of established 
biomarkers of plaque vulnerability, such as C-reactive protein (CRP) [11], may 
also lead to the diagnosis of patients with high-risk atherosclerotic lesions.  
Despite the great progress made in diagnostic technology, timely 
identification of vulnerable plaques remains a challenge. Multiple imaging 
modalities, both invasive and non-invasive, have been proposed; among which 
intravascular ultrasound (IVUS) is the most promising. Clinical studies with 
IVUS have successfully identified characteristic features of vulnerable plaques, 
such as a lipid-laden necrotic core and a thin fibrous cap. Consequently, 
physicians have now started using IVUS routinely in cath-labs during 
intervention, making early diagnosis of vulnerable plaques a real possibility. 
 
1.3 TREATMENT OF VULNERABLE PLAQUE  
Proposed clinical strategies for diffusing vulnerable plaques mainly 
involve i) reducing the propensity to rupture by changing plaque composition or 
by improving endothelial function, and ii) reducing blood thrombogenicity. The 
former is referred to as plaque stabilization, and the latter as plaque passivation. 
Plaque stabilization can be achieved by decreasing LDL content, and reducing 
inflammation in atherosclerotic plaque through local or systemic administration of 
drugs, or by controlling diet. These conclusions, supported by animal studies [12-
14], provide the rationale for treatment of vulnerable plaques. 
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1.3.1 Current practices and proposed treatment options  
It is well recognized that vulnerable plaque is only the focal manifestation 
of a disease that is systemic at its root. Systemic drugs such as Statins (lipid-
lowering agent) and Aspirins (antithrombotic agent) are preventing a substantial 
portion of events in patients. According to well-regarded clinical studies, patients 
treated with Statins have consistently lower rates of cardiac events than control 
subjects (see Figure 1.5). Aspirin, on the other hand, has been shown to be 
effective in reducing the risk of forming blood clots. Physicians have, therefore, 
widely adopted systemic drugs as a viable prospective way to prevent cardiac 
events. However, the majority of these events are still left to occur. Therefore the 
goal is to augment the benefits that Statins provide, to help treat patients acutely 
and thus more effectively, and achieve a 0% event rate through artery-specific 
therapies.  
 
Figure 1.5: Sample of four key studies that appeared in top peer-reviewed 
publications that show significant reduction in number of events 
compared to control subjects. A huge unmet need still exists that can 
be targeted. [15-18] 
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There are important practical considerations that make the local drug 
delivery concept particularly attractive due to certain limitations of systemic 
therapy. Although many of the commonly used medications in cardiovascular 
medicine have positive effects on long-term plaque stabilization, the time course 
of these changes is unclear. In some cases, reduction in plaque lipid content or 
thrombogenicity can take as long as six months. Additionally, possible side 
effects like bleeding complications resulting from antithrombotic drugs pose a 
serious health concern. Local drug delivery takes care of these problems by 
providing concentrated targeted therapy acutely with a much smaller amount of 
drug. This ensures a high local drug tissue concentration and minimal systemic 
loss or side effect. Therefore, it is reasonable to conclude that a combined 
treatment approach incorporating both local and systemic administration of anti-
thrombotic and lipid-lowering drugs may provide rapid treatment of vulnerable 
plaques as well as long-term prevention of acute coronary syndrome.  
1.4 LOCAL DRUG DELIVERY SYSTEM 
Recent advances in diagnostic technology and interventional cardiology 
have made targeted therapy, taking patient-specific artery wall geometry and 
plaque characteristic into account, a viable treatment option. In developing these 
local drug delivery systems, a multitude of clinical and design issues need to be 
considered. For example, a local drug delivery system should produce a high local 
drug concentration within the therapeutic window while reducing systemic 
leakage. Possible candidates for such drug delivery platforms include catheter-
based delivery systems and drug eluting stents. These devices may deliver drug 
 9 
directly, or through local delivery vehicles, such as liposomes, shaped particles, 
polymeric nanoparticles, and so on (see Section 1.4.2). This work focuses on 
catheter-based delivery devices that use polymeric nanoparticles as drug carriers.  
 
 
Figure 1.6: Schematic of the lumen-side drug delivery concept. [19] 
 
1.4.1 Luminal drug delivery product concept 
In a typical luminal drug delivery mechanism, a catheter is usually 
inserted in the groin. With the aid of live angiographic images, the physician 
guides the catheter through the artery into the heart until it reaches the target site 
of the diseased coronary artery. The catheter then releases a solution containing 
the drug-encapsulated delivery vehicle of choice (e.g., nanoparticles) radially into 
the arterial lumen. Following the tissue uptake of this solution, the delivery 
vehicles transport through the wall mainly via diffusion and advection while 
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releasing the encapsulated drug. The released drug then travels through the wall 
and provides therapeutic effect to the targeted region (see Figure 1.6). 
This concept provides regional treatment of the atherosclerotic plaque in a 
timely manner that results in sustained reduction in plaque progression. It is a 
relatively safe deliverable product concept that adds value over systemic therapy. 
1.4.2 Nanoparticles as delivery vehicles 
In recent years, polymeric nanoparticles (NPs) have generated a great deal 
of interest in the medical device community as effective drug delivery vehicles 
because they can provide controlled release of drug, achieve targeted delivery 
through surface modification, protect the drug from degradation, and reduce 
systemic toxic effect [20]. These are usually 20-500 nanometer (nm) polymeric 
spherical particles with the drug encapsulated within the polymer. 
 
          
       (a)   (b)  (c) 
Figure 1.7: Examples of different drug delivery vehicles. (a) Liposome (b) shaped 
particles (c) polymeric nanoparticles [21]. Drug release rate is 
governed by drug diffusion and polymer degradation. 
Since the nanoparticles can carry only a limited amount of drug, predictive 
models have been developed to describe mass transport of drug within a 
polymeric system to assist in the design of an optimized formulation. The tailored 
drug release rate profile obtained from these models serves as an essential 
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ingredient in developing a coupled arterial mass transport model simulating the 
local drug delivery system (further discussed in Section 2.2.2). 
1.5 MOTIVATION 
The application of these medical devices in treating patients with high-risk 
lesions in a clinical setting can be challenging. This is mainly because of key 
design issues that need to be resolved on a case by case basis prior to treatment 
administration, including:  
 
• delivery platform and location to use for maximum efficacy,  
• type of vehicle to use to achieve targeted delivery, 
 
which require performing specific tasks with some degree of reliability, for 
example, 
 
• quantitative prediction of local drug distribution in the artery wall,  
• evaluation of the effect of physiological forces on local drug distribution, 
• tuning of the drug release rate profile to the temporal sequence of the 
target biological process in the affected region. 
 
Experimental techniques are unable to address these critical design and 
targeting issues as they prove to be unsafe and often non-feasible to be performed 
in vivo on human patients. Numerical tools are particularly useful in this regard 
because they can provide crucial information that is otherwise unavailable. 
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Therefore, there is a pressing need for building technologies that will use 
mathematical models on patient-specific geometries to determine optimum drug 
design parameters, such as delivery location, delivery mechanism, drug release 
rate profile, vehicle size, vehicle surface properties, drug viscosity, etc., for a 
desired drug tissue concentration in the arterial wall. This work aims to address 
this need by developing a computational tool to support the design and analysis of 
a catheter-based local drug delivery system, and thus to make a useful 
contribution in the prevention of acute coronary syndrome.  
The computational tool developed can help analysis by determining 
simple metrics like mean residence time (MRT) to measure the effectiveness of 
different drug delivery configurations. Additionally, dominant dimensionless 
numbers can be identified through a nondimensional analysis. Results can reveal 
the influence of parameters, such as drug diffusivity that may be tuned to better 
design novel drug release mechanisms from the nanoparticles. Moreover, when 
applied to a three dimensional (3D) patient-specific geometry, this tool will be 
able to capture essential 3D aspect of the physiological transport phenomenon 
more realistically, and thereby help tailor clinical strategies to individual patients. 
Using the temporal and spatial drug distribution data for the arterial tissue, 
physicians can assess treatment efficacy for a specific patient, saving potential 
cost of ineffective treatments.  
1.6 MODELING OF COUPLED TRANSPORT OF DRUG AND DRUG-
ENCAPSULATED NANOPARTICLES 
In developing such a complex model that involves incorporating a 
multitude of physiological factors, a few practical issues from a modeling 
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perspective need to be considered. For example, in the catheter-based lumen side 
delivery system, the radial release of nanoparticles in the bloodstream takes place 
over a few cardiac cycles, while the drug transport in the artery wall continues for 
days. Because of such a significant difference in time-scales, it is reasonable to 
confine the numerical simulations to the artery wall—decoupled from the lumen. 
This work, therefore, primarily focuses on the coupled transport of drug and drug-
encapsulated nanoparticles in the coronary artery wall. The lumen-side 
contribution was incorporated in the model through appropriate boundary 
conditions. 
It is well established that arterial wall mass transport is governed by 
diffusive and advective effects, and therefore can be described by linear scalar 
advection-diffusion equations [22-25]. However, metabolic consumption of drug 
by the wall tissue also plays an important role in drug transport through the artery 
wall. A first order reaction can be applied to incorporate this metabolic decay of 
drug [24, 26-28]. Furthermore, recently it has been shown [29] that realistic 
patient specific 3D geometry is an essential ingredient in creating physiological 
flow and transport features necessary for developing catheter-based drug delivery 
design procedures. Therefore, a comprehensive 3D advection-diffusion-reaction 
model to provide generality was warranted.  
The various arterial wall mass transport models available in the literature 
deal with a variety of species, including LDL [27, 28, 30-32] as well as pure drug 
for local delivery by intravascular infusion through a porous membrane [33],  
stent-platform [23, 34, 35], and catheter [36]. To the author’s knowledge, there is 
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no existing comprehensive 3D tool to numerically simulate coupled transport of 
drug and drug-encapsulated nanoparticles with application to a local drug delivery 
system. In previous studies, the artery wall has been modeled as either single 
layered [28, 30, 31, 37], or multilayered [24, 27, 32, 38-40] where it is divided 
into its constituent layers, namely intima, media and sometimes, adventitia. Most 
of these models consider the wall to be a rigid porous medium [26-28, 30-32, 34, 
41] commonly using Darcy’s law, or a poroelastic medium [36, 42]. For this 
work, at first a 3D model of a healthy idealized coronary artery—a straight 
cylindrical tube with a rigid homogenous wall, was considered. The model was 
then modified to incorporate a more sophisticated representation of wall structure 
that includes the intima, internal elastic lamina (IEL), the media, external elastic 
lamina (EEL), and the adventitia. Finally, computations were carried out on a 
patient-specific solid NURBS (Non-Uniform Rational B-Splines) coronary artery 
geometry under both healthy and diseased condition where the diseased condition 
was represented by the presence of a vulnerable plaque. 
In the next few chapters, the coupled mathematical model will be 
described in detail, followed by the numerical procedures, and the artery wall 
geometries used to solve the mathematical problem. The results are presented in 




In this section, the coupled transport modeling theory for the two species 
will be described in detail. The conservation principle for chemical species can be 
represented by the following partial differential equations (PDEs)—the scalar 
transport equations in terms of concentrations. 
2.1 THE COUPLED DRUG TRANSPORT MODEL IN CARTESIAN COORDINATES 
Let Ω be an open, connected, bounded subset of d, d = 2 or 3, with 
piecewise smooth boundary
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, representing Dirichlet and Neumann 
boundaries, respectively.  ! = !+ "!  denotes the fixed spatial domain of the 
problem and  n  denotes the unit normal to Γ. In the strong form, the boundary 
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= Concentration of drug, gm-mole/cm3 








= Diffusivity tensor for the drug, cm2/s 
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I  = Metabolism rate constant for the nanoparticles, 1/s 
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        = Fraction of drug released from each spherical nanoparticle at time t 
(see [43]). 
 
Equations (1) and (2) are, respectively, the linear scalar advection-
diffusion-reaction equation for drug-encapsulated nanoparticles (species I) and for 
the drug (species II)⎯both the encapsulated drug and any free drug that may be 
present in the formulation. Here the velocity field  u(x,t)  is given and assumed 
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solenoidal, i.e.,  ! "u = 0 . The term 
 
! " uC( )  represents advection, that is, the 
velocity field that carries the scalar; the term 
 
!C !t  represents accumulation, 
 !C  is the metabolic reaction term, and  ! "(K "!C)  is the diffusion term. K can 
be a full, symmetric and positive-definite second order tensor representing 
anisotropic diffusion. There is a one-way coupling between the two transport 




f  in Eq. (2) accounting for the rate at which 
drug is released from the nanoparticles. 
Given an initial distribution of concentration as stated in Eqs. (7) – (8), the 
governing equations, Eqs. (1) – (2), can be solved subject to an appropriate set of 
boundary conditions. Eqs. (3) – (4) denote Dirichlet boundary conditions, and 
Eqs. (5) – (6) represent Robin type boundary conditions where g, C∞,  !  (mass 
transfer coefficient with the unit cm/s), and 
 
!  (specified normal flux into Ω) are 
given functions (time-dependent in general) on the appropriate portion of the 
boundary with the subscripts I and II denoting the two species.  
2.2 REDUCTION TO CYLINDRICAL COORDINATES 
In the literature, typical physiological diffusivities are described in 
transmural (radial), and planar (circumferential and axial) directions (see Figure 
2.1) due to the inherent cylindrical structure of the artery. In the medical device 
industry most in-house experiments for estimating physiological parameters and 
validating drug release rate models are carried out in a cylindrical coordinate 
setting. Furthermore, clinicians are more comfortable in interpreting results 
referred to a cylindrical domain, which is more intuitive. Therefore the 
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Figure 2.1:  Cylindrical coordinate system. 
This section will describe the coupled drug transport modeling theory in 
cylindrical coordinates with appropriate boundary conditions. The mathematical 
model can be described in four parts as follows. 
 
2.2.1 Modeling of drug transport 
The governing equations for the coupled drug transport model can be 































































































































































































Omitting subscripts I and II for simplicity, Dr, Dθ, and Dz are the 
diffusivities of the respective species in radial, circumferential, and axial 
directions, respectively, such that Di, j = D0i, jϕi(r, t), where i = r,θ,z and j = I, 
II. Similarly, Vr, Vθ, and Vz are the corresponding advective velocities in the 
artery wall such that, Vi = Vi,0ϕi(r,t), where i = r,θ,z. The thickness of the artery 
wall is denoted b. Here, D0i  and Vi,0 are reference values of the diffusivity and the 
advective velocity, respectively, and ϕi(r,t) is a space and time varying function 
accounting for the spatial and temporal variation of these quantities. A physical 
assumption has been made here that the diffusivity tensor has principle directions 
in the r,θ, and z coordinate directions (see Eq. (31)) in accordance with the 
experimental data available in the literature where it has been cited that diffusion 
in the circumferential and axial directions is faster than that in the radial direction 
for typical drugs of interest (see Chapter 4). 
The governing equations (9) and (10) are derived for the most general case 
in 3D cylindrical coordinates. The first three terms represent diffusion of scalars 
in r,θ and z direction respectively. These are followed by three terms describing 
transport by advection in the three coordinate directions. The seventh term, that is 
the reaction term, denotes metabolic decay of drug in the tissue. Identical to their 
Cartesian counterparts, the two transport equations are coupled through the source 
term CIf. 
In the numerical examples presented later (see Section 5.1), a 
dimensionless form of the model will be used. To derive the dimensionless 
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;  (14) 
and 























Here the concentration of the nanoparticles CI, was non-dimensionalized 
by the initial concentration of nanoparticles in the formulation CI,0, while that for 
the drug CII was non-dimensionalized by the initial concentration of free drug in 
the formulation CII,0. The non-dimensionalized variables are listed in Table 2.1.  
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   Table 2.1: Nondimensional variables used 
Notation Definition 
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*   r / b  
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2.2.2 Modeling of drug release rate from nanoparticles 
Drug release from the nanoparticles was assumed to occur solely by 
diffusion. A biphasic diffusion model [44], originally devised for predicting drug 
release from a drug eluting stent (DES) coating [45], was adopted and extended to 
polymeric nanoparticles as the drug concentration in the polymer within the 
nanoparticles is sufficiently high. This biphasic model is based on the assumption 
that transport through the dispersed drug phase within the nanoparticles takes 
place via two discrete modes – the fast mode and the slow mode. The fast mode is 
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the release of drug from highly percolated structure of drug phase within the 
polymer, and the slow mode is the release of drug from a non-percolated polymer-
encapsulated phase of the drug. The model has been previously validated against 
experimental data and the assumption of biphasic state of drug phase encapsulated 
within polymer has been corroborated [45], making this concept a natural choice 
for modeling the drug release rate from the polymeric nanoparticles.  
This biphasic drug release rate model developed for the monodisperse case 
(i.e., same-sized particles) was further enhanced and extended to the polydisperse 
case (nanoparticles in the formulation having a range of particle sizes). The 
































































where, M/M0 is the percent release of drug from all the nanoparticles at time t 
with M0 denoting the total weight of drug encapsulated in all the nanoparticles, N0 
(total number of nanoparticles). Consequently, the nondimensionalized drug 
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Figure 2.2: Predictive values of drug release from nanoparticles for monodisperse 
and polydisperse case. [44] 
There are three major design parameters, effective diffusivity of slow drug D1, 
effective diffusivity of fast drug D2, and fraction of drug in slow phase f1, which 
by manipulating one can obtain a desired release rate profile. Additionally, the 
drug release rate (RR) can be tailored by mixing different sizes of nanoparticles in 
the polydisperse case, which provides two additional design parameters, R, the 
size of the ith nanoparticle in the mixture, and αi, the fraction by weight of the ith  
nanoparticle in the formulation. This adds to the flexibility in designing an 




2.2.3 Boundary conditions 
To determine appropriate boundary conditions for the lumen side boundary, 
the following physiological phenomena were considered.  
• The loss of particles and free drug accumulated in the wall due to their 
exposure to blood flow in the lumen that tends to wash them away from 
the wall into the bloodstream. 
• Their propensity to stick/un-stick to the wall depending on the reaction 
rate (sticking coefficient) for the particular species. 
• And finally, the solubility of the particles in the tissue compared to the 
blood serum through partition coefficients for each species. It is a measure 
of differential solubility of the chemical substance between two solvents 
where one of the solvents chosen is typically water. Hence the partition 
coefficient normally indicates how hydrophilic or hydrophobic a chemical 
substance is. 
 
The above physiological phenomena were modeled as follows (see Figure 2.3).  
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Figure 2.3: Schematic diagram of the cross-section of an artery to explain the 
boundary conditions.  



















































































1. The expressions for exponential loss at the lumen side, Eq. (19) for the 
nanoparticles and Eq. (23) for the drug, were obtained by applying 
unsteady state mass balance for the nanoparticles and the drug in the thin 
film volume of thickness h and an area A0 at the lumen side boundary (see 
Figure 2.3), and then analytically solving for concentrations with 
appropriate boundary conditions. 
2. In determining the lumen-side boundary condition for the nanoparticles, it 
was assumed that backward reaction rate in Eq. (18) is considerably 
slower compared to the forward reaction rate or the sticking coefficient.  
3. For the adventitia-side boundary, a Robin type boundary condition was 
implemented as presented in Eqs. (26) – (27). As km→ ∞, it reduces to a 




2.2.4 Modeling of solute permeation across tissue (IEL) barrier  
The species transport across the internal elastic lamina (IEL) between the 
two homogeneous parts, the intima and the media, were simulated by 
implementing Kedem and Katchalsky’s model for solute transport across tissue 
barrier [46]. Assuming quasi-steady state, that is, the time for the solute to diffuse 
across this membrane is much faster than the time for the solute concentration to 
























 = solute flux per unit area, cm/s 
J
v




 = reflection or retardation factor  
C
1
= solute concentration in solvent on the intima side (normalized) 
C
2
= solute concentration in solvent on the media side (normalized) 
P = diffusive permeability of the membrane to the solute, cm/s  
 
 
Figure 2.4: Modeling of species transport across the IEL barrier. 
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The permeabilityP is related to the diffusion coefficient of the membrane, 
D
m








where  K  is the partition coefficient. Eq. (28) accounts for both diffusive and 
advective transport. When Peclet number, Pe  is less than 1.2, the advective 
contribution can be neglected [46]. In the intima the species transport is highly 
diffusion dominated, that is, Pe <  1 . Hence Eq. (28) for the solute flux across 









)  (30) 
2.3 JUSTIFICATION FOR THE VELOCITY VECTOR AND THE DIFFUSIVITY 
TENSOR 
The physiological diffusivities Dr, Dθ, and Dz, provided by the medical 
device design community can be converted to a diffusion tensor K in Cartesian 
coordinate using the formulae presented here. Computations can then be carried 
out in Cartesian coordinates suitable for complex geometries, using the numerical 
procedures detailed in Chapter 3. 
 
Figure 2.5: Transition from cylindrical to Cartesian coordinates. 
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.  (31) 
 
The circumferential, radial and axial directions in cylindrical coordinates 
are associated with corresponding ξ, η and ζ directions, respectively, in the 
Cartesian description of the geometry. The resulting full 3 by 3 diffusion tensor in 
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In the above formulation,  J is the Jacobian as defined in Eq. (34). The 
column vectors of the Jacobian are orthonormalized according to the Gram-
Schmidt process, which is expressed in Eq. (33). The corresponding advective 




1. Procedures outlined in Eqs. (31) – (36) are simple to carry out in the 
isogeometric discretization due to the suitable parametric definition of the 
geometry. On the other hand, extracting this information from a general, 
3D, unstructured hexahedral or tetrahedral mesh is not a simple task. This 





3.1 WEAK FORM OF THE CONTINUOUS PROBLEM 
Let  S  denote the trial solution and  V  weighting function spaces. Defining 
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denotes the L2 -inner product on  Q = {!,"} .  
3.2 DISCRETIZATION  
Let  S
h
! S  and  V
h
! V  be the finite-dimensional spaces of trial 
solutions and weighting functions, respectively. The semi-discrete formulation for 
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Eqs. (46) − (53) represent a stabilized formulation of advection-diffusion-
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 is the inverse Jacobian of the element mapping between the parent and the 
current coordinates of the physical domain and  !t  is the time step. This 
stabilization is appropriate for the window of Peclet numbers under consideration 
that can range from 0.1 to 1000 depending on the tissue properties of the artery 
wall under healthy and diseased condition (see Chapter 4). 
Spatial discretization of the one-way coupled problem makes use of 
isogeometric analysis based on NURBS, an alternative to standard finite elements, 









,  x ! "  (59) 
denote a set of basis functions defined on all of  !  to be used for the drug 
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are the associated control variables. This reduces to usual shape functions and 














}  denote the vectors of degrees of freedom 






}  and  CII = {CII }  represent the vectors of 
degrees of freedom of concentration for species I and II, respectively. The above 
discretization when combined with the formulation of (46) − (58) yields two 




































































drug  represent the nanoparticle and drug transport residuals for 
the Ath basis function, respectively. 
3.3 TIME INTEGRATION AND NUMERICAL IMPLEMENTATION 
With the equations in semi-discrete form, a time integration scheme is 
introduced, namely, the generalized-α method proposed by Chung and Hulbert 
[49] and Jansen, Whiting and Hulbert [50]. This method seeks to solve the system 
for time tn+1 given the computed quantities at time tn such that the nonlinear 
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A one-parameter family of second-order accurate and unconditionally stable time 
integration schemes is obtained by defining γ employing the following 





























 are chosen in order to ensure accuracy and stability of 
the method. For first-order equations in time, Chung and Hulbert in [49] 
demonstrated that the method is second-order accurate and unconditionally stable 
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" [0,1]  is the spectral radius of the amplification matrix 
as  !t !"  that controls high frequency damping [50].  
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, the following 
predictor-corrector solution strategy is used with a single corrector step. 
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Corrector stage: 
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• Use these α-level values to assemble the residual and the tangent 






preconditioned GMRES (Generalized Minimal Residual Method) 
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At this point a nanoparticle field is calculated at the next time step.  Now 
the drug concentration is obtained as 
 



















n  (83) 
Corrector stage: 
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• Use these α-level values to assemble the residual and the tangent 
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It may be worth noting that the residuals in (67) and (68) are evaluated at 
intermediate time steps while the derivatives in (79) and (87) are taken at time 




Parameter Selection and Solution Approach 
4.1 MODELING CONSIDERATIONS FOR THE ARTERY WALL GEOMETRY  
Coronary artery walls are multilayered with distinct features present in 
each homogenous component. When an artery becomes diseased, it undergoes 
significant changes morphologically that affect material and hence transport 
properties. In this section the salient features of a healthy and a diseased artery 
wall are described as a prelude to approaching the central theme of this chapter, 
that is, the selection of relevant parameters for both healthy and diseased artery 
cases presented in Section 4.2. 
4.1.1 Healthy artery 
Figure 4.1 shows a typical artery wall composition in detail.  An 
appreciable amount of specialization is evident even at this macro level: 
• Endothelium—a monolayer of flat cells lining the arterial wall that 
separates it from the lumen. Very thin with a mean thickness of 4.6 µm. 
• Intima—the innermost layer containing connective tissue and a few 
smooth muscle cells. 
• Internal Elastic Lamina (IEL)—a very distinct, usually folded, 
membrane composed of elastic tissues with fenestral pores separating the 
intima from the media. 
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• Media—a thick layer, containing alternative layers of connective tissue 
(collagen fibers and elastic fibers) and smooth muscle cells. 
• External Elastic Lamina (EEL)—a thin membrane that separates the 
media from the adventitia. 
• Adventitia—the outermost covering of the vessel composed of loose 
connective tissue. Adventitia in most large arteries contains lymphatics 




Figure 4.1: Healthy artery wall model. A typical artery wall composition, taken 
from [25]. This is a schematic of the longitudinal cross-section of 
artery wall geometry. Typical dimensions can be found in Table 4.1. 
Transmural diffusion is driven by the steep concentration gradient across 
the artery wall created by the metabolic consumption of drug that takes place in 
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the media. On the other hand, the lymphatics and vasa vasorum in the adventitia 
constantly drain solutes from the extra-cellular space. There is experimental 
evidence that the adventitia poses a substantially lower resistance to transport 
compared to the media, even without the clearance through the adventitial 
microcirculation [52]. Due to this fast diffusion of drug through the adventitia, it 
has been argued that there is no appreciable concentration gradient across the 
thickness of this layer. Therefore, the adventitia can be considered as a large sink 
for molecules that diffuse across the intima and the media through the extra-
cellular space. This phenomenon can be mimicked by a sink type boundary 
condition (a constant concentration that can be higher than the average medial 
concentration) at the media-adventitia interface. These observations allow 
lumping of the adventitia and replacing it with a Robin type boundary condition at 
the media-adventitia interface as detailed in Section 2.2.3. Therefore in this work 
two homogeneous layers, the intima and the media separated by the IEL, were 
considered ignoring the endothelium and adventitia. Their contributions were 
incorporated through appropriate boundary conditions. 
A medium to large sized healthy human coronary artery wall can be on an 
average 1 mm in thickness. Table 4.1 lists the dimensions of these two constituent 
layers of a typical Left Anterior Descending (LAD) coronary artery wall for both 
a healthy and a diseased artery as reported in [53]. The values in parentheses are 
the averages of all the thickness data taken from histomorphological studies 
referred to in [54]. Since the thickness of the intima and media vary widely with 
age, gender, disease condition and stage, etc., it is very difficult to select a 
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representative idealized artery wall model. The selected dimensions for the two 
main homogeneous layers under consideration, intima and media, are provided in 
Table 4.1 (the last two rows in green) with their corresponding material properties 
presented in Section 4.2.  
Table 4.1: Coronary artery wall dimensions in mm. [53, 54] 




Adventitia 0.54±0.2 0.92±0.2 
Wall thickness 
without Adventitia 
0.46 to 0.5 
(0.4 to 0.5) 
0.98 to 1.0 
(0.6 to 0.9) 
Intima + Media 0.34±0.1 
 
0.78±0.3 
Intima thickness <0.3 
choose 0.15 
0.65 
Media 0.35 0.35 
4.1.2 Diseased artery with a vulnerable plaque  
The arterial remodeling associated with the disease process does not affect 
the media significantly, while the intima thickens appreciably because of lipid 
accumulation and the resulting smooth muscle cell proliferation (see Table 4.1). 
Figure 4.2 illustrates these morphological changes (see Sections 1.1 − 1.2 for a 
more detailed account) that lead to the formation of vulnerable plaques 
characterized by two distinct regions within the intima, a large lipid-rich necrotic 
core (> 40% of plaque area) and a fibrous cap (< 165 µm) that separates it from 





Figure 4.2: A schematic of the disease process in an artery wall. A) A cross 
section of a normal coronary artery, B) Intima thickening and lipid 
accumulation, C) Formation of a vulnerable plaque with a necrotic 







4.2 PARAMETER SELECTION 
The solution of the coupled transport model relies on a number of physical 
parameters; each of them may vary over a wide range, depending on 
physiological conditions. This makes modeling a bit of a challenge because there 
is a dearth of physiological data in the literature. In this section the parameters 
selected for both normal and diseased artery cases are presented. These 
parameters have been chosen in accordance with experimental evidence or some 
rationalization based on previous experiences that are consistent with typical drug 
transport scales. The major parameters used and the rationales behind their 
selection are discussed below. 
4.2.1 Advective velocity  
The interstitial space of arterial tissue can be thought of as a network of 
channels and pores. The fluid path is rather tortuous in the void space of this 
porous medium. As the structures of the pores are not known for arterial tissue, a 
continuum approach is used to describe the fluid flow in porous medium where 
the porous medium is assumed to be of uniform material as proposed by Darcy in 
1856. According to Darcy’s law the fluid velocity is proportional to the 
hydrostatic pressure gradient in a homogeneous and isotropic medium. A 
hydrostatic pressure difference of 60 to 100 mm Hg exists across the artery wall 
tissue resulting in advective transport from the lumen toward the adventitia. As an 













assumed to be spatially uniform and only the radial component is considered to be 












= 0.  (90) 
In the literature, where it is often referred to as filtration velocity, typical 
values of the radial velocity are of the order of 10-6 cm/s [22, 39, 42, 55]. Initial 
computations for the 1D case, and then the 3D axisymmetric case, were carried 
out with the advective velocity value obtained from the physiological Peclet 
number, Pe for the drug of interest. With a diffusivity 10-9 cm2/s, a Peclet number 
of Pe ≈ 0.1 (typically Pe <1) was assumed to be representative of physiological 
conditions for the drug Everolimus (similar to Sirolimus and Rapamycin 
presented later in Section 4.2.3 as drugs of interest). This assumption was largely 
based on previous experience with experiments investigating transport behavior 
from drug eluting stents [56]. A summary of these parameters can be found in 
Table 4.1. However for the 3D multilayer artery wall models, both the idealized 
and patient-specific geometry, parameters were selected based on experimental 
data as described below. 
According to Meyer et al. [22], filtration velocity has been experimentally 
measured to be 1.78e-6 cm/s for a transmural pressure jump of 70 mm Hg across 
the artery wall. This has been found to be consistent with the numbers reported by 
Tarbell et al. [57] and Huang et al. [58], as reported in [25]. Since larger 
molecules are reflected by the porous structure of tissue resulting in retarded 
advective flow, the filtration velocity is multiplied by a sieving coefficient, γ, to 
account for this phenomenon.  
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Table 4.2: Summary of some parameters 
Parameter Unit Species I  Species II Comment Ref. 
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0  cm2/s 10e-9 Everolimus in calf carotid artery  [56] 
!  1/s 0 ≈ 10e-5 0.006/hr for Everolimus  [56] 
b cm 0.1 Thickness of a typical porcine 
coronary artery 0.8 ± 0.2 mm. 
 [59] 








 1/s (1.65e-6) 
- For the NPs 
 [56] 
 
km  cm/s (10e-5)1 2.44e-7 




Factor - 1 1-2 fluid-solid interface  
h cm 0.001    
                                                
1 Items within parentheses are assumed properties based on typical drug transport time scales. 
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As a starting point, the advective velocity is assumed to be the same across 
the artery wall for both the nanoparticles (NP) and the drug. From Table 4.2, the 






!  !  = 1.78e-




 for the 
drug Paclitaxel in bovine carotid arteries to be 3.2e-7 cm/s with a transmural 




= 3e-7 cm/s 
appears to be a reasonable approximation for the radial component of advective 
velocity. 
4.2.2 Metabolic reaction rate 
The importance of the reaction term depends on the drug used, tissue 
characteristics, and other physiological factors. The reactive term acts as a sink 
for drug concentration. A typical value for the consumption rate for LDL is 10-4 
1/s [25].  For Everolimus, in-house data [56]  indicate a rate of 0.006/hr ≈ 10-5 1/s. 
For the nanoparticles, this parameter is set to zero as these nanoparticles are not 
assumed to be biodegradable in the calculations. 
4.2.3 Effective diffusivity and permeability 
4.2.3.1 Healthy artery 
Nanoparticles 
Drug-encapsulated polymeric nanoparticles are typically 50 − 200 nm 
hydrophobic spherical particles. The transport properties of these NPs are 
comparable with those of macromolecules like LDL (MW ≈ 2500 kDa), which 
are 25 − 50 nm and likewise hydrophobic/lipophilic (with affinity to lipid) in 
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nature. Vafai et al. [25] reported the following parameters for macromolecular 
transport in artery walls based on the work of Karner et al. [24], Stangeby and 
Ethier [30], and references therein.  
 
Table 4.3: Nanoparticle transport properties for different artery wall layers based 
on [25] 
Properties Endothelium Intima IEL Media Ref. 
Diffusivity, D (cm2/s) 8.145e-13 5e-8 3.18e-11 5e-10  [25] 
Porosity, ε 0.0005 0.96 0.004 0.15  [27, 30, 38, 
58, 62] 
Effective diffusivity,  
Deff (cm2/s) 
4.08e-16 4.8e-8 1.27e-13 7.5e-11  
Permeability, P (cm/s)   1.59e-7   [24] 
Sieving Coefficient, γ 0.0145 0.171 0.171 0.134  [25] 
Filtration velocity, ufilt 
(cm/s) 
1.78e-6  [22] 
 
In Table 4.3, the effective diffusivity for each homogeneous wall layer 
was computed by multiplying free diffusivity with porosity accounting for 
hindered diffusion through the arterial structure. The effective diffusivity for the 
nanoparticles was assumed to be isotropic due to lack of data in the literature with 
evidence to the contrary (unlike hydrophobic drugs which show clear evidence of 
anisotropic diffusion). Furthermore, assuming that both LDLs and NPs are large 
molecules compared to the solvent water, according to the Stokes-Einstein 
theorem, the diffusivity should be inversely proportional to the radius of the 
solute. Therefore, the effective diffusivity for LDL (in green) has been scaled by a 
factor of 5 since typical LDL size is 25 − 50 nm whereas NP size is usually 
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somewhere between 50 to 200 nm. The parameters used in the simulations are 
listed in Table 4.4. 
Table 4.4: Nanoparticle transport properties used for different artery wall layers 
Properties Intima IEL Media 
Effective diffusivity, Deff (cm2/s) 9.6e-9  1.5e-11 
Permeability, P (cm/s)  3.14e-8  
Drug 
Low molecular weight (MW) hydrophobic drugs have shown appreciable 
therapeutic effect in local drug delivery systems [63]. For this work, 
immunosuppressant drugs Rapamycin or Sirolimus (0.954 kDa) and Paclitaxel 
(0.854 kDa) were selected as representative drugs for the luminal drug delivery 
system of interest. These are hydrophobic or lipophillic drugs commercially used 
in drug eluting stents. These drugs have been studied extensively by Edelman and 
co-workers [23, 60, 61, 64, 65] for their arterial transport properties. Table 4.4 
lists effective diffusivities and permeabilities for different hydrophobic species 
found in the literature along with their corresponding sources. 
Table 4.5: Transport properties of different hydrophobic compounds  
 Intima IEL Media Ref. 
 Species \ Properties Dz, Dθ Dr DIEL PIEL Dz, Dθ Dr  
Rapamycin (0.954 kDa) 6e-5 8e-8  (1e-7) 6e-7 8e-10  [65] 
Paclitaxel (0.854 kDa) 7e-5 2e-8  (1e-7) 7e-7 2e-10  [65] 
HRP (44 kDa)   2.4e-11 2.4e-7    [66] 
Albumin (66 kDa)   2.4e-10 2.4e-62  1.3e-8  [67] 
 
                                                
2 Based on IEL thickness of 1 micrometer. Numbers withinin parentheses are estimated values. Numbers in green 
correspond to the References. 
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There is a three order of magnitude difference between the effective 
diffusivities in planar ( θ and z), and radial (r) directions in the media. On the 
other hand, the diffusivities in the intima are in general approximated to be one 
hundred times faster than that in the media according to Huang et al. [26]. This 
observation is in essence supported by Hwang et al. in [64], where it has been 
argued that neo-intimal diffusivity and planar medial diffusivity should be of the 
same order because of absence of elastin fiber barriers in the region. Hence the 
diffusivities in the intima were approximated to be two orders of magnitude 
higher than that in the media, as presented in Table 4.5. 
Tarbell et al. [38] observed that for low Peclet number flows, IEL pore 
structure, and consequently IEL permeability, had a significant influence on tissue 
uptake and medial concentration for a low molecular weight solute like 
Adenosine Tri-Phosphate or ATP (0.507 kDa). On the other hand, for a high-
molecular-weight (MW) solute LDL with a convection-dominated flow through 
the interstitial space, the medial tissue uptake was not affected by IEL pore 
structure. Extrapolating these results to the drugs of interest (MW approximately 
0.8-0.9 kDa), Rapamycin and Paclitaxel are expected to be transported by a 
diffusion-dominated mechanism ( Pe < 1) and, influenced greatly by the IEL pore 
structure.  
Penn et al. [66] reported IEL permeability in rat aorta for a tracer enzyme 
Horseradish Peroxide, HRP (≈ 44 kDa) to be  2.4e-7 cm/s, whereas, Fry et al. [68] 
found IEL permeability in dog aorta for albumin (≈ 66 kDa) to be  one order of 
magnitude greater than that, that is ≈ 2.4e-6 cm/s (assuming IEL thickness of 1 
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micrometer). But this could be due to facilitated transport of protein. Considering 
the fact that Sirolimus and Paclitaxel have lower MW than HRP and may not 
show protein (say albumin) facilitated transport to the same degree, it is 
reasonable to expect the drug IEL permeability to be somewhere in between that 
for HRP and albumin. Hence it was approximated to be ≈ 1e-7 cm/s. 
4.2.3.2 Diseased artery 
Although there exists animal models with lipid-rich or neointimal (due to 
restenosis) lesions, drug transport properties through these lesions are not 
available in the literature due to their wide range of variability. However, 
researchers have shed some light on the possible behavior of these drugs under 
diseased conditions based on their observations regarding the general transport 
properties in healthy arteries. For example, drug diffusion in hyperplastic 
neointimal layer should be isotropic because there is little variation in smooth 
muscle cell orientation in this region. Similarly, this observation can be extended 
to the vulnerable (lipid-laden) plaque and isotropic diffusion can be attributed to 
both the fibrous cap and the lipid core. Furthermore, while hydrophobic drugs and 
nanoparticles will have a higher affinity to the lipid core, both the IEL and the 
atherosclerotic plaque act as barriers to macromolecular (i.e., NP) transport. So is 
the case with drug transport but to a lesser degree [64]. On the other hand Lee et 
al. [69] concluded that the IEL does not pose a significant barrier between the 
intima and the media in the atherosclerotic process, indicating that IEL 
permeability for drugs may be higher in diseased arteries compared to healthy 
ones. There seems to be a lack of consistent data in the literature quantifying the 
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variability in transport properties induced by the disease process. Therefore, the 
diseased artery was simulated largely by incorporating geometric and structural 
modifications (along with their corresponding material properties) caused by the 
progression of atherosclerosis, for example, lipid accumulation, intima thickening 
and fibrous cap formation, while keeping the transport properties for the unaltered 
layers (i.e., the healthy part of the intima and the media) the same as in the 
healthy case. This is a major assumption that needs to be further investigated 
through a sensitivity analysis. 
The fibrous cap is made of collagen fibers and smooth muscle cells. With 
increasing collagen content, the diffusivity through the extra cellular matrix 
decreases [70]. Hydrophobic drug Retinoic acid (≈ 0.3 kDa) has a permeability of 
120e-4 cm/hr with a partition coefficient of 18 in collagen film. With collagen 
film viscosity of about 100 cp, Retinoic acid diffusivity is reported to be 3.25e-4 
cm/hr [71]. But intuitively, for a larger molecule like LDL, effective diffusivity 





















the effective diffusivity for the NPs can be roughly estimated to be Dfc = 4.5e-9 
cm2/s. The effective drug diffusivity in the fibrous cap was derived applying the 
same rationale (see Table 4.6). 
In the diseased case, the extra-cellular space of the necrotic core is rich in 
lipid content. Properties of lipid/oil, such as olive oil, can be used to represent the 
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transport behavior of this drug through the lipid core [72]. The viscosity of olive 
oil is about 85 times that of water. The Stokes-Einstein relation predicts the 
diffusion coefficient for LDL to be 85 times less in oil. Therefore, assuming 
structural hindrance (porosity) characteristics are similar to the intima, the 
diffusivity of the nanoparticles in lipid core is determined by scaling Dintima by a 
factor of 85 to get Dlipid = 1.13e-10 cm2/s. On the drug side, due to its high affinity 
to lipid, hindrance due to binding and unbinding (often referred to as reversible 
binding) of the drug to lipid or protein sites need to be accounted for. As a crude 
approximation, the effective diffusivity of Paclitaxel in olive oil was computed 
from its diffusivity in blood [73] and then scaled by octanol-water partition 
coefficient for the drug (≈ 104.5) [56], as proposed by Taylor et al. [40], to get the 
effective drug diffusivity in the lipid core. Table 4.6 lists the transport properties 
used for the diseased parts of the artery wall. 
Table 4.6: Transport properties of nanoparticles and the drug in the diseased parts 
of the artery wall 3 
Species Properties Fibrous cap Lipid core 
NP Effective diffusivity,  
Deff (cm2/s) 
4.5e-9 1.13e-10 




4.2.4 Boundary conditions 
Using the parameters presented in Table 4.1 that appear in the lumen-side 
boundary condition equations introduced in Section 2.2.3, the resulting time 
                                                
3 Properties for the diseased portion only. For the intima, IEL and  the media see Tables 5.2 and 
5.3 
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varying concentration for the nanoparticles and the free drug that may be present 
in the formulation are as shown in Figure 4.3 and Figure 4.4, respectively. The 
nanoparticles partition into the artery wall and reach a maximum concentration 
within a few minutes of administration, after which, they slowly deplete to zero in 
approximately 21 days. This is a consequence of competition between the rate of 
forward reaction (“sticking”) and backward reaction (“un-sticking”) of 
nanoparticles. The forward and backward reaction rates or sticking coefficients 
are design parameters for the nanoparticles that are often manufactured to have 
special surface characteristics to enhance sticking. Based on experiences in the 




= 1/10 per minute with a time 




 = 1/10080 per minute 
with a time constant of 7 days were chosen.  
        (a)            (b) 











 is not negligible. 
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In the 1D (Section 5.1) and 3D axisymmetric (Section 5.2) calculations it 






, which implies that once the nanoparticles partition 
into the tissue at the lumen-side boundary, they remain attached for the time 
period under consideration, that is 7 days of simulation time (see Figure 4.3a). 





 is not negligible (see Figure 4.3b). 
 
Figure 4.4: Lumen-side boundary condition for the free drug present in the 
formulation. 
The formulation released into the bloodstream by design may contain free 
drug in addition to the drug encapsulated within the nanoparticles. Typically 
anywhere from 40 to 200 mg of free drug is added to the solution for every 200 
mg of drug that is encapsulated in the nanoparticles. This is one of the design 
parameters that can be tweaked for better efficacy. In this work, a formulation of 
220 mg of free drug for 200 mg of encapsulated drug was used to determine if 
there is a noticeable effect of the presence of free drug on drug distribution. 
Figure 4.4 depicts the exponential loss of the free drug to blood flow at the lumen-
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side boundary where it takes about 6 hours for the drug to be completely washed 
away. 
An investigation of the effect of adventitia-side boundary condition on 
drug distribution revealed that there is little or no difference in the time-varying 
concentration profiles within the artery wall between zero-flux and zero-sink type 
boundary condition, especially in regions away from this boundary. A similar 
observation was made by Yang and Vafai in [39] where it was demonstrated that 
LDL concentration in intima, IEL and media are independent of the boundary 
condition at this media-adventitia interface. A zero concentration sink boundary 
condition was employed at the adventitia-side for both species, as it appeared to 
be the natural choice for reasons explained previously in Section 4.1.2. 
4.2.5 Drug release rate 
Typically, by design, the nanoparticles release 30% of the entire drug 
encapsulated by the end of day 1, and a 70% release is achieved by the end of first 
week [56]. Manipulating the design parameters D1, D2 and f1 in the bi-phasic drug 
 
Figure 4.5: Tailored bi-phasic (monodisperse case) drug release rate profile used 
in the simulations achieving a 30% drug-release by day 1, and a 65% 
release by day 7. 
 59 
release model presented previously in Section 2.2.2, the resulting drug release rate 
profile used in the simulations is presented in Figure 4.5. 
 4.3 SOLUTION APPROACH 
Isogeometric analysis employing quadratic NURBS was used for spatial 
discretization. As a first approximation, the arterial wall was assumed rigid in 
computations for simplicity, as the primary focus was placed on the transport-
reaction formulation. A residual-based multiscale method was used to solve the 
coupled transport equations while generalized−α method was adopted for time 
advancing. The numerical code was first verified against a simple 1D pure 
diffusion problem with known analytical solution (see Appendix A). Then 
simulations were run for 7 days with a time step of 2 minutes on several 3D 
NURBS-based geometries of interest.  
The YZβ discontinuity capturing method [74] was employed to address 




Application to Idealized Artery Geometry 
A cubic geometry of unit dimensions was generated to verify the in-house 
numerical code developed against a 1D diffusion problem with known analytical 
solution (see Appendix A) and to study the effect of dominant dimensionless 
numbers on drug distribution (see Section 6.1). This model was further utilized in 
the selection of an optimal discretization for a set of physiological parameters (see 
Table 4.2). Since nanoparticles (NPs) have a very low diffusive coefficient, often 
of the order of  10!12  cm2/s, they tend to stay close to the lumen side boundary 
over a considerable duration of time. To capture nanoparticle transport in this so-
called boundary layer, the mesh was refined near the boundary as shown in the 
Figure 5.1. This 1D mesh was then mapped onto the 3D idealized cylindrical 
geometry with the dimensions shown Figure 5.1b in accordance with typical 
values found in the literature (see Table 4.1).  
5.1 IDENTIFICATION OF DOMINANT PARAMETERS 
A study of the effect of dimensionless numbers, namely Peclet number 
and Damkohler number, on drug distribution was carried out in order to gain 
insight into the parameter sensitivity of drug distribution. The equations for the 
coupled transport model as detailed in Sections 2.1 − 2.3 were solved using the 
solution approaches presented in Section 4.2. The computations were performed 





Figure 5.1: NURBS meshes used: (a) Cubic mesh for 1D analysis (b) 3D 
cylindrical single-patch NURBS mesh for the idealized healthy 
coronary artery wall segment model. 
Pe = [0.01 to 1] while keeping Da constant, and 
Da = [1.7 to 1700] while keeping Pe constant,  
Here the species subscripts were omitted for simplicity. 
 
Table 5.2 shows the time evolution of drug concentration over the 
thickness of the artery wall for four different cases. In all four cases, drug 
concentration increases sharply with distance to a peak value before decreasing 
(at a slower rate) asymptotically to zero for all times. With time this peak 




follows the transport of the nanoparticles (NPs), because at a given time, the 
depth of penetration of the peaks is the same for all Pe or Da. 
Drug transport is a diffusion dominated process, hence, the purely 
diffusive case, Pe = Da = 0 (see Table 5.2a) was considered first. The response of 
the system with varying Pe and Da was studied with respect to this reference 
case. 
5.1.1 Effect of Peclet number on drug distribution 
The Peclet number compares the diffusion term in the direction of the 
motion to the advective component. To investigate the influence of advective 
velocity on drug distribution compared to diffusion, simulations were carried out 
for three different values of Peclet number within physiological ranges. A 
comparison of Table 5.2(a) and (b) shows that although the concentration profiles 
maintain the same shape in general, the peaks are now sharper with increasing Pe. 
A decreasing Pe essentially brings about a sharp drop in the peak concentration 
value at all times. 
Figure 5.3 demonstrates a strong influence of advective velocity on drug 
distribution. A higher concentration and a deeper penetration of drug can be 
observed due to advective forces acting on the nanoparticles, as well as the drug 
released from them. This can be expected since the advective velocity acting 
radially carries the nanoparticles, and hence the released drug away from the wall. 
At later times a more uniform distribution is observed. There is a possibility of the 
solution becoming unrealistic beyond a critical Pe, a hint of which can be seen in 










      (c)      (d) 
Figure 5.2: Drug concentration in the arterial wall at various times during 
simulation for the cases:  (a)  Pe = 0,  Da = 0; (b)  Pe  = 0.1,  Da = 0; 










Figure 5.3: Influence of Peclet number on drug distribution. Concentration of 
drug at different cross-sections of the artery: (a) r = 0.1 mm or 1/10 
depth, (b) r = 0.25 mm or 1/4 depth, and (c) r = 0.33 mm or 1/3 
depth of the artery thickness.  
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5.1.2 Effect of Damkohler number on drug distribution 
Damkohler number can be defined as the ratio of diffusive time scale and 
metabolic reaction time scale. It quantifies the relative importance of chemistry 
with respect to fluid dynamics. In other words, Damkohler number represents the 
time for a chemical reaction to occur relative to the time it takes a particle to 
diffuse through the control volume. 
Figure 5.4 depicts drug distribution at four increasing values of Da. A 
higher Da expedites the drug consumption and reduces concentration while 
preserving the concentration profile shapes at fixed times. Variation of 
concentration with Da though negligible at initial times, becomes significant at 
later instants. The concentration profiles seem to flatten and then decrease linearly 
with time. As the Da is increased in steps of one order of magnitude, from 2 to 
20, the concentration does not diminish as drastically as it does beyond that point, 
i.e., from Da ≈ 20 to 200, or 200 to 2000. 
A comparison of Figure 5.2(a) and Figure 5.2(c) reveals comparable drug 
distribution with concentration values remain within 1%. Though the peak value 
and the shape of the concentration profiles are preserved for all times, drug 
penetration suffers noticeably with increasing Da. This trend is repeated when 
Figure 5.2(b) and Figure 5.2(d) are compared as well.  
To summarize, both the Peclet number and the Damkohler number are 
dominant in the transport process. Effect of varying Pe is similar to that of Da, 




   (a)       (b) 
 
 
   (c) 
Figure 5.4: Influence of Damkohler number on drug distribution. Concentration of 
drug at different cross-sections of the artery: (a) r = 0.1 mm or 1/10 
depth, (b) r = 0.25 mm or 1/4 depth, and (c) r = 0.33 mm or 1/3 
depth of the artery thickness. 
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5.1.3 Effect of boundary conditions on drug distribution 
 
An investigation of the effect of adventitia-side boundary condition on 
drug distribution demonstrated that there is little or no difference in the time-
varying concentration profiles between zero-flux and zero-sink type boundary 
condition. The shape of the concentration profiles (see Figure 5.5) remains 
essentially the same for all times. However, there is a slight change in 
concentration near the adventitia-side boundary for the non-zero sink type 
boundary condition case. Here the constant concentration at the boundary forces a 
slight rise in concentration values near the adventitia. Even then, the presence of 
drug in the adventitia side does not affect drug distribution near the in the intima 
or the media and the concentration profiles remain the same in both size and 
shape, up to 60% depth into the artery wall. These observations are in agreement 












               (c) 
Figure 5.5: Influence of adventitia-side boundary condition (B.C.) on drug 
distribution. Concentration of drug in the arterial wall at various 
times for: (a) zero flux B.C., (b) zero sink B.C., and (c) nonzero sink 
B.C. where normalized concentration at the boundary is 0.01.  
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5.2 DRUG DISTRIBUTION IN A 3D HOMOGENEOUS ARTERY WALL MODEL 
In a healthy artery wall, the media makes up almost 2/3 of the inner artery 
wall (intima-media) thickness. Therefore, for simplicity it was assumed that a 
single layer homogeneous wall model with just the media was sufficient to 
capture the overall artery wall transport characteristics. Initial calculations were 
performed on this geometry to produce axisymmetric results and to compare these 
results with those of the multi-layer realistic artery wall model in order to gain an 
appreciation for the effect of wall inhomogeneity on drug distribution. 
Using the parameters in Table 4.1, and applying the same numerical 
procedures in Section 3.1-3.3 and solution approach described in Section 4.3 (as 
in the 1D case) simulations were carried out for the idealized cylindrical 
homogeneous coronary artery wall model (see Figure 5.1) for two specific cases: 
Case 1: No free drug in the formulation  
Simulations were run for 7 days assuming the formulation released into 
the bloodstream did not contain free drug, that is, the entire drug was 
encapsulated within the nanoparticles. This implies that the drug concentration for 
the lumen side boundary was set to zero for all times. Results are presented in 
Figure 5.6 where the distribution of the nanoparticles and the drug are displayed 
side-by-side at various times. Since transport in the artery wall is a diffusion 
dominated process, the very low nanoparticle diffusivity makes the nanoparticle 
penetration barely noticeable in these pictures even after 7 days. A close-up view 
is provided in Figure 5.7, which shows evidence of very slow penetration of the 
artery wall, by the nanoparticles. On the other hand, the drug penetrates 
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approximately 1/8 of the thickness of the artery in 24 hours, while it takes about 7 
days for the drug to reach about 1/3 of the thickness of the artery (qualitatively). 
Case 2: With free drug in the formulation 
Same simulations were carried out for 7 days assuming the formulation 
released into the bloodstream contained free drug in addition to the encapsulated 
drug within the nanoparticles. Figure 4.4 depicts the time varying lumen-side 
boundary condition for the drug used for this case.  
Results are presented in Figure 5.8, which shows the spatial distribution of 
the drug at various times. Drug distribution data for the first few hours confirms 
the decaying of free drug concentration at the lumen-side boundary due to their 
loss to blood flow in the lumen. By the end of day 1 the entire free drug is washed 
away from the lumen-side boundary and drug concentration reaches a minimum. 
From that point onward, drug concentration picks up gradually with time (see 
concentration for day 4 and then day 7), and penetration depth increases as the 
slowly moving nanoparticles act as a source of drug, much like in Case 1. Over a 
period of 7 days, the depth of penetration by the drug is approximately the same 
with no significant difference in concentration compared to Case 1. This 
demonstrates the effect of free drug in the formulation, which can provide an 
initial burst of high drug concentration near the wall, after which it is up to the 
slow and controlled release of the drug from the nanoparticles to provide the 
necessary therapeutic effect. 
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  (a)       (b) 
       
  (c)       (d) 
          
  (e)      (f) 
Table 5.6: Temporal and spatial distribution of drug-encapsulated nanoparticles 
and the drug with no free drug in the formulation (Case 1). 
Nanoparticle concentration in the arterial wall at:  (a) t = 1 hr, (c) t = 
1 day, (e) t = 7 days. Corresponding drug concentration at: (b) t = 1 
hr, (d) t = 1 day, and (f) t = 7 days. 
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  (a)        (b) 
 
                 
  (c)       (d) 
 
                 
  (e)       (f) 
Table 5.7: A close-up view of the temporal and spatial distribution of drug-
encapsulated nanoparticles and the drug with no free drug in the 
formulation (Case 1). Nanoparticle concentration in the arterial wall 
at various instants during simulation:  (a) t = 1 hr, (c) t = 1 day, (e) t 
= 7 days. Corresponding drug concentration at various instants 
during simulation: (b) t = 1 hr, (d) t = 1 day, and (f) t = 7 days. 
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 (a)    (b)    (c) 
 
 
 (d)    (e)    (f) 
 
 
 (g)    (h)    (i) 
Table 5.8: Temporal and spatial distribution of drug with free drug in the 
formulation (Case 2). Drug concentration in the arterial wall at 
various instants during simulation:  (a) t = 1 hr, (b) t = 2 hrs, (c) t = 3 
hrs, (d) t = 4 hrs, (e) t = 5 hrs, (f) t = 6 hrs, (g) t = 1 day, (h) t = 4 
days, and (i) t = 7 days. 
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5.3 DRUG DISTRIBUTION IN A 3D MULTILAYER ARTERY WALL MODEL 
As presented previously in Section 4.1, the coronary artery wall model 
under consideration is comprised of mainly two concentric layers, 1) the intima, 
2) the media, with IEL separating the two homogeneous parts. Starting out with 
an idealized normal artery wall model, a straight cylindrical tube with wall 
composition divided into its constituent layers of anatomically relevant 
dimensions with appropriate material properties assigned, a vulnerable plaque 
characterized by a fibrous cap and a lipid pool underneath was incorporated in the 
coronary artery segment to study the effect of plaque heterogeneity on drug 
distribution under diseased conditions.  
5.3.1 Drug distribution in a normal artery wall  
In this section, the application of the computational tool-set to an idealized 
multilayered coronary artery wall model under healthy condition is discussed. The 
details of the geometric model and the corresponding NURBS mesh generated are 
presented in Figure 5.9a and 5.9b respectively. Using the parameters selected for 
this case (Section 5.2) and applying the solution approach described in Section 
5.3, the mathematical model was solved for 7 days with a time step of 2 minutes. 
The results are discussed below. 
Figure 5.10 shows the temporal and spatial distribution of nanoparticles in 
terms of concentration normalized against the initial concentration of 
nanoparticles available at the lumen-wall interface for tissue uptake. Nanoparticle 
transport in the intima is diffusion dominated ( Pe < 1). Diffusivity through the 
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intima is almost three orders of magnitude higher than that in the media. As a 
result it takes less than an hour for the nanoparticle “diffusion” front to reach the 
IEL and about 6 hours for it to spread throughout the intima. From there onward, 
nanoparticle distribution remains fairly uniform across the intima at any given 
time. This agrees well with the work of Vafai et al. [25] and references therein. 
Note the axisymmetric nature of distribution. 
 
              
  a)     b) 
Figure 5.9: a) The idealized normal coronary artery wall geometry with a lumen 
diameter of 3.5 mm and 0.5 mm wall thickness. The intima makes up 
approximately 1/3 of the artery wall thickness. b) The corresponding 
mesh consisting of 2240 NURBS element. 
The IEL poses a barrier to nanoparticle transport. It takes an appreciable 
concentration gradient to develop across the IEL for the nanoparticles to 
overcome this resistance and penetrate the media (see B and C in Figure 5.10). 
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However, once the front reaches the media around t = 12 hours, it is mostly the 
advective forces ( Pe > 1) that drives it through this slowly diffusive region 
toward the adventitial sink. There is a steep concentration gradient ahead of the 
front, while the concentration of nanoparticles in the region behind this front 
becomes largely uniform because of advective forces sweeping the nanoparticles 
away from the IEL. In about 48 hours the so-called “diffusion” front reaches the 
adventitia and starts clearing out through the adventitial sink. By day 4, the spatial 
distribution of nanoparticles is more or less uniform throughout the artery wall 
and reaches the same concentration level as that at the lumen-side boundary, 
which depletes slowly over time due to the loss of nanoparticles through the 
blood-wall interface. At the end of day 7 this uniform nanoparticle concentration 
reduces to 10% of the initial (at t = 0) lumen-side boundary concentration. 
Drug transport shows a similar behavior to that of the nanoparticles, 
demonstrating the coupled nature of transport. Figure 5.11 depicts the temporal 
and spatial distribution of drug in the artery wall at different points in time during 
simulation. Drug concentration appears to be substantially lower in the intima 
compared to the rest of the artery wall. Furthermore, evidence of drug movement 
through the intima is barely noticeable.  
A closer inspection of drug transport behavior during early times with a 
better time resolution provides a few useful insights (see Figure 5.11c). Although 
diffusion is relatively fast, drug distribution is not uniform in the intima during 
this time as suggested by Figure 5.11a. In fact a positive concentration gradient 
(opposite to the direction of advective flow) develops within a few hours of 
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administration due to accumulation of drug against the IEL barrier. This can be 
explained by considering a couple of factors discussed below.  
In diagrams I and J of Figure 5.11c, there is evidence of free drug 
penetration into the intima. The concentration gradient (higher drug concentration 
at the lumen-side boundary) drives the free drug into the tissue largely by way of 
diffusion ( Pe < 1). However, with time, the free drug source at the lumen-wall 
interface decreases exponentially and it becomes a sink for drug within 6 hours of 
nanoparticle administration in the lumen. In the meantime on the nanoparticle 
front, aided by a constant (or very slowly decreasing with a significantly higher 
timescale of depletion) source at the lumen-side boundary, the nanoparticles 
penetrate the intima significantly within the first hour (see Figure 5.10a), and then 
starts accumulating near the IEL barrier. Although initially the free drug was a 
significant source of drug in the intima, within a few minutes the nanoparticles 
take over as the primary source, and then within a few hours, become the only 
source of drug. Therefore, as demonstrated in diagram C of Figure 5.11a, drug 
concentration becomes higher away from the lumen-side boundary as a direct 
consequence of a higher nanoparticle concentration in that region (see 
corresponding nanoparticle distribution in Figure 5.10). This creates a 
concentration gradient in a direction opposing the advective flow. Diffusive 
forces drive the drug toward the lumen (acting against the opposing advective 
forces) where it gets washed away by the blood flow. The intima never becomes a 
region of high drug concentration because of this fast depletion of drug through 
the lumen side boundary. The ratio of time constant for the exponential loss of 
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drug and advective time scale through the intima dictates the relative rate of 
depletion of drug through the lumen side.  
Interestingly enough, according to Figure 5.11a(B) as well as Figure 
5.11c(L), there is a hint of surge in drug concentration in the intima around t = 1 
hour, which implies that the drug gets trapped within the intima in 
synchronization with the nanoparticles (see Figure 5.10a(B)). As soon as the 
nanoparticles are able to overcome the IEL resistance and make their way into the 
media, drug concentration in the media increases substantially. Hence, medial 
concentration of drug is largely dependent on the extent of penetration of 
nanoparticles beyond the IEL barrier. This implies that there may not be a 
significant build up of drug concentration gradient across the IEL barrier for it to 
overcome because of its fast depletion through the lumen. Hence, a sharp increase 
in drug concentration can be observed in the media at t = 12 hours even though 
there is not a significant buildup of drug on the intima side of the IEL. Here the 
source of drug is largely the nanoparticles. Contribution from the intima side 
appears to be negligible. 
The motion of the drug diffusion front in the media gets retarded by the 
metabolic decay or binding of drug to binding sites spread all over the media. 
Furthermore, because of this consumption of drug a region of lower drug 
concentration can be found lagging behind the diffusion front (essentially the NP 
front) in the media unlike the nanoparticles. By the end of day 7 the artery wall 
becomes free of drug due to its clearance through the adventitial sink and 
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metabolic consumption in the media. Figure 5.12 provides a side-by-side 
comparison of the nanoparticle and drug distributions at various times. 
 
 80 
A) B)    
C)  D)  
Figure 5.10a: Distribution of nanoparticles in an idealized coronary artery wall 
segment under normal condition at A) t = 2 mins, B) t =1 hr, C) t = 6 
hrs, and D) t =12 hrs in terms of concentration (normalized). 
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E)  F)  
G) H)  
Figure 5.10b: Distribution of nanoparticles in an idealized coronary artery wall 
segment under normal condition at E) t = 1 day, F) t = 2 days, G) t = 
4 days, and H) t = 7 days in terms of concentration (normalized).  
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A) B)  
C) D)  
Figure 5.11a: Drug distribution in terms of concentration (normalized) in an 
idealized coronary artery wall segment under normal condition at A) 
t = 2 mins, B) t = 1 hr, C) t = 6 hrs, and D) t = 12 hrs.  
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E) F)  
G) H)  
Figure 5.11b: Drug distribution in terms of concentration (normalized) in an 
idealized coronary artery wall segment under normal condition at E) 
t = 1 day, F) t = 2 days, G) t = 4 days, and H) t = 7 days. 
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I)  J)  
K)  L)  
 Figure 5.11c: Drug distribution in terms of concentration (normalized) in an 
idealized coronary artery wall segment under normal condition at I) t 




Figure 5.12a: Distribution of nanoparticles (left) and the drug (right) in an 
idealized coronary artery wall segment under normal condition at t = 





Figure 5.12b: Distribution of nanoparticles (left) and the drug (right) in an 
idealized coronary artery wall segment under normal condition at t = 





Figure 5.12c: Distribution of nanoparticles (left) and the drug (right) in an 
idealized coronary artery wall segment under normal condition at t = 





Figure 5.12d: Distribution of nanoparticles (left) and the drug (right) in an 
idealized coronary artery wall segment under normal condition at t = 
4 days (top) and t = 7 days (bottom), in terms of concentration 
(normalized). 
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5.3.2 Drug distribution in a diseased artery wall with a vulnerable plaque 
A vulnerable plaque model with a lipid core encased by a very thin fibrous 
cap was incorporated in the idealized multilayered cylindrical wall model. The 
plaque dimensions were determined by the necrotic core angle, radius of the 
artery lumen and relative core thickness [75]. For a plaque with a necrotic core 
arc angle of θ = 85 degrees, the core thickness can be approximated to be b = 0.5 
mm with a longitudinal plaque length of c = 5 mm. Fibrous cap thickness is 
typically less than 90 µm. The idealized plaque was placed at the center of the 
artery wall segment. Figure 5.13 shows the NURBS mesh generated for this 




Figure 5.13: A cut-away view of the idealized diseased artery wall mesh, 




Figure 5.14:  Diseased artery wall model with a vulnerable plaque. This is a 
schematic of the transverse cross-section of the artery wall (bottom) taken half 
way through the longitudinal length, highlighting the lipid rich necrotic core 
encased by the fibrous cap of the vulnerable plaque, along with the longitudinal 
cross-section of the artery wall model (top) showing increased intimal thickness. 
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 The diseased artery has been modeled to have four distinct regions with 
varying diffusive properties, where 
 
Dinima > Dfc > Dmedia > Dlipid . While the 
healthy part of the diseased artery shows a similar transport behavior to that of a 
normal artery as discussed in Section 6.3.1, for the diseased part it is considerably 
different. In fact, the existence of the plaque has a significant bearing on the 
overall drug distribution within the artery wall. The temporal and spatial 
distribution of nanoparticles is presented in Figure 5.15. Note the distribution is 
highly 3D in nature. 
Much like the healthy or normal artery case, there is fast diffusion of 
nanoparticles within the intima, making the intimal concentration fairly uniform. 
On the other hand, though the nanoparticles penetrate the fibrous cap fairly 
quickly, the radial transport through the lipid core is slow and retarded. As a 
result, while the nanoparticles reach the IEL within an hour in the healthy parts, 
there is hardly any penetration of the lipid core (the target region). Soon enough 
these nanoparticles start migrating from the healthy part of the arterial media into 
the diseased portion by way of planar diffusion (isotropic). Therefore, it can be 
said that the healthy part of the artery wall essentially acts as a nanoparticle 
reservoir and enhances transport to the diseased part. 
The nanoparticle concentration in the lipid core reaches a maximum 
within 24 to 48 hours. After this period, it diminishes with time. By the end of day 
4 the nanoparticle distribution becomes largely uniform throughout the artery 
wall. 
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Figure 5.15 shows the corresponding time evolution of drug concentration 
in the diseased artery. Drug diffusion is highly anisotropic, that is, diffusivity in 
the planar direction is almost three orders of magnitude faster than the radial 
direction. The much faster planar diffusion (anisotropic) facilitates drug transport 
into the diseased part significantly. A comparison of item F in Figure 5.15b with 
that of Figure 5.16b illustrates this point very well. At time t = 48 hours, there is 
an appreciable spatial variation of nanoparticle concentration. The highest 
nanoparticle concentration occurs in the healthy part of the media and the lipid 
core within the diseased part of the same cross-section. The corresponding drug 
distributions show a slightly different picture. The medial concentration of drug is 
fairly uniform on both the healthy and diseased sides, indicating that in addition to 
the drug released from the nanoparticles that have made their way into the 
diseased part, much of the drug comes from the healthy part of the media (a high 
nanoparticle concentration area) because of faster planar diffusion. Therefore, 
although the radial transport of drug through the lipid core never makes it to the 
media, this influx of drug from the planar (circumferential and axial) direction 
substantially increases the medial drug concentration earlier than expected 
(between 24 to 48 hours of administration). 
Furthermore, during this time period, the lipid core attracts and 
accumulates the hydrophobic drugs released from the nanoparticles trapped 
within. This provides a long residence time for the drugs, enhancing their 
potential therapeutic effect in the target region.  
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After reaching a maximum around day 2, drug concentration in the lipid 
core diminishes due to its transport to the surrounding outer intima with a two 
orders of magnitude faster diffusivity. The medial concentration suffers a similar 
fate because of this so called dumping of drug in the intermediate intima layer, in 
addition to the medial consumption of drug. By the end of the week, the diseased 




A)      B) 
 
C)      D) 
Figure 5.15a: Distribution of nanoparticles in an idealized coronary artery wall 
segment with a vulnerable plaque under diseased condition at A) t = 
2 mins, B) t = 1 hr, C) t = 6 hrs, and D) t = 12 hrs in terms of 
concentration (normalized).  
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E)      F)  
 
G)      H) 
Figure 5.15b: Distribution of nanoparticles in an idealized coronary artery wall 
segment under diseased condition characterized by a vulnerable 
plaque at E) t = 1 day, F) t = 2 days, G) t = 4 days, and H) t = 7 days 
in terms of concentration (normalized). 
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A)      B) 
 
C)      D) 
Figure 5.16a: Drug distribution in an idealized coronary artery wall segment with 
a vulnerable plaque under diseased condition at A) t = 2 mins, B) t = 





E)      F) 
.  
G)      H) 
Figure 5.16b: Drug distribution in an idealized coronary artery wall segment 
under diseased condition characterized by a vulnerable plaque at E) t 




Application to Patient-Specific Geometry 
A chain of specific procedures, referred to as the vascular modeling 
pipeline, developed by Zhang et al. [76] has been used to construct hexahedral 
solid NURBS for patient-specific geometric modeling of the Left Coronary Artery 
(LCA) directly from CT imaging data. Figure 6.1 illustrates the steps in building 
this geometric model using a portion of the coronary arterial tree of a healthy over 
















                   (a)                           (b)                    (c)                   (d)                          (e)  
Figure 6.1: Skeleton-based sweeping method and meshing. (a) isocontour of 
LCA, (b) path, (c) sweeping along the path—templated circle 
translated and rotated to each cross-section, (d) solid NURBS mesh, 






The hexahedral solid NURBS model for the lumen generated by Zhang et 
al. (see Figure 6.1) was modified to include an artery wall of uniform thickness 
surrounding the lumen using isogeometric modeling techniques [47]. The lumen 
boundary was extended radially by 15% of the radius of the lumen. This 
generated an artery wall with a thickness of 0.6 mm approximately, which was 
then decoupled from the lumen to obtain the patient-specific coronary artery wall 
geometry. 
6.1 DRUG DISTRIBUTION IN A NORMAL ARTERY WALL 
Figure 6.2 shows the details of the healthy artery wall model. There are 
four patches along the length of the LCA with each patch again split into two 
concentric patches at approximately 1/3 depth into the artery wall thickness. The 
inner patch represents the intima, while the outer patch represents the media. This 
geometric discontinuity at the intima-media interface was essential to implement 
the Kedem-Katchalsky model for concentration jump condition across the IEL 
(see Section 2.2.4). The corresponding NURBS mesh used in the simulations can 
be found in Figure 6.3. 
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Figure 6.2:  Schematic of the cut away view of a healthy patient-specific left 
coronary artery segment showing the intima in green and the media 
in blue. A cross-section is taken along A-A’ highlighting these two 




Figure 6.3: A cut-away view of the three-dimensional hexahedral NURBS mesh 
used for the normal (healthy) patient-specific coronary artery wall 
segment used in simulation. The artery geometry was divided into 
four NURBS patches along the length of the segment, while each of 
these patches were split in two along the radial direction at the 
location of the internal elastic lamina. The model consists of 121, 
212 control points, solved over 7 days with a time step of 2 minutes. 
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The nanoparticle wall deposition for the patient specific artery was 
obtained from a complementary work carried out by Calo et al. [36]. The 
simulation setup is shown in Figure 6.4. A catheter releases drug-encapsulated 
nanoparticles radially into the lumen, with/without free drug in the solution, of the 
same coronary artery segment under consideration, that is, the LCA over six 
cardiac cycles. Although blood flow washes away the majority of these 
nanoparticles, some of the nanoparticles marginate toward the artery wall. Here 
the assumption is that the particles that reach the outer diameter of the lumen are 
available for tissue uptake. A Navier-Stokes solver coupled to the scalar 
advection-diffusion equation was used in a computational framework to get the 
temporal and spatial distribution of nanoparticles at the wall. The wall deposition 
thus obtained was then normalized against the highest nanoparticle concentration 
to get the spatial distribution of nanoparticles at the lumen-wall interface (see 
Figure 6.5). Quite expectedly, the nanoparticles accumulate near the bifurcation 
area. Flow through this recirculation zone is delayed as the residence time of 
circulating elements is prolonged. Such flow separation has been reported to 
enhance platelet [77] and thus nanoparticle deposition. 
 103 
 
Figure 6.4: Schematic describing the problem setup for the simulation of catheter-
based local drug and drug-encapsulated nanoparticle delivery. [36] 
 
 
Figure 6.5: The nanoparticle wall deposition data at t = 0 that acts as the lumen 
side boundary condition for the artery wall transport model, 
decoupled from the lumen. 
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In Figure 6.6, the location of the three representative transverse slices are 
presented, which are taken in order to investigate time evolution of local drug 
distribution in a healthy patient-specific coronary artery segment. These locations 
were chosen such that the results can be compared with those for the diseased 
artery case, where slice 1 goes through the vulnerable plaque (see Figure 6.13). 
Slice 2 and 3 are there to provide insight into the effect of plaque heterogeneity on 
overall drug distribution of the artery wall segment, hence, will be discussed with 
the diseased case in Section 6.2. 
 It has already been established that the spatial distribution of 
nanoparticles at a given point in time greatly influences local drug distribution. 
Due to this closely coupled nature of transport between the two, the time 
evolution of drug can be best understood if it is analyzed side-by-side with the 
nanoparticles. 
Let us first consider slice 1 which happens to be at a region with a 
relatively dense wall deposition of nanoparticles. This spatial variation in the 
nanoparticle concentration at the lumen side boundary has a significant effect on 
the overall time evolution of nanoparticle distribution, and therefore drug 
distribution, when compared to the idealized case where the nanoparticle wall 
deposition was uniform at the lumen-side boundary. As the nanoparticles near the 
more dense wall deposition region penetrate the intima radially (see Figure 6.8a), 
one can clearly see nanoparticle movement in the circumferential direction within 
the intima due to comparable planar diffusion (isotropic). Hence, they are now 
able to access areas that did not have a significant wall deposition at the outset. 
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This implies that although nanoparticle wall deposition may be highly localized, 
once they penetrate the artery wall, they tend to spread out toward a more uniform 
distribution. 
Similar to the idealized case, the nanoparticles (where available) largely 
remain within the intima during the first 12 hours since their release, though their 
distribution is more 3D in nature. Apart from this variation in spatial 
concentration introduced by the inhomogeneous initial wall deposition, the overall 
nanoparticle transport characteristics are comparable to the idealized case because 
of its assumed isotropic diffusion.  
Drug distribution on the other hand is no longer axisymmetric and shows 
considerable variation compared to the idealized case because of the cumulative 
effect of a number of factors.  First thing to note is the relatively low intensity of 
drug concentration compared to the ideal case as a direct consequence of two 
phenomena. Firstly, the spatial variation of nanoparticle concentration within a 
wide range of values, which means for a given control volume, the number of 
nanoparticles at play here is significantly lower than in the idealized case. 
Secondly, due to the 3D nature of the problem, the considerably faster planar 
(both circumferential and axial) diffusion drives much of the drug away from 
these pockets of higher concentration of nanoparticle that translates to higher drug 
availability. 
According to Figure 6.9 and 6.10 the drug appears to accumulate 
preferably at a specific region. This pocket of higher drug concentration first 
appears around 6 hours into the simulation. With time this region grows wider in 
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the planer direction up to a maximum, after which it starts depleting. A close 
inspection of Figure 6.10b(E) reveals a slow emergence of another region with 
localized high drug concentration at approximately 120 degrees to the first one.  
The growth and shrinking of this high concentration region may be 
attributed to the initial burst of drug release from nanoparticles such that the drug 
availability peaks around 24 hours, then diminishes with time (see Figure 4.5). 
Consequently, drug concentration reaches a peak at the end of day 1 at these two 
locations. 
Apart from that, this peculiar behavior of localization of drug to create a 
high concentration region is most likely a consequence of 3D geometry induced 
complex transport forces at play. Interestingly, these two so-called pockets are 
located at either end of the higher nanoparticle concentration region (the yellow 
band in item E of Figure 6.8b) that appears in the media at t = 24 hours. The 
highly anisotropic drug diffusivity coupled with the cumulative effect of 
nanoparticle wall deposition in the surrounding area may have had a 




Figure 6.6: Schematic of the patient-specific coronary artery model under normal 
condition, showing the location and orientation of the slices 1, 2 and 
3 under consideration. 
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A)      B) 
  
C)      D) 
Figure 6.7: Distribution of nanoparticles at slice 1 of the patient-specific coronary 
artery wall segment under normal condition at A) t = 2 mins, B) t = 8 
mins, C) t = 16 mins, D) t = 30 mins in terms of concentration 
(normalized).  
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A)      B) 
 
C)      D) 
Figure 6.8a: Distribution of nanoparticles at slice 1 of the patient-specific 
coronary artery wall segment under normal condition at A) t = 2 
mins, B) t = 1 hr, C) t = 6 hrs, and D) t = 12 hrs in terms of 
concentration (normalized).  
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E)      F) 
 
G)      H) 
 
Figure 6.8b: Distribution of nanoparticles at slice 1 of the patient-specific 
coronary artery wall segment under normal condition at E) t = 1 day, 
F) t = 2 days, G) t = 4 days, and H) t = 7 days in terms of 
concentration (normalized).  
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A)      B) 
 
C)      D) 
Figure 6.9: Drug distribution at slice 1 of the patient-specific coronary artery wall 
segment under normal condition at A) t = 2 mins, B) t = 8 mins, C) t 
= 16 mins, D) t = 30 mins, in terms of concentration (normalized). 
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A)      B) 
 
C)      D) 
Figure 6.10a: Drug distribution at slice 1 of the patient-specific coronary artery 
wall segment under normal condition at A) t = 2 mins, B) t = 1 hr, C) 
t = 6 hrs, and D) t = 12 hrs in terms of concentration (normalized). 
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E)      F) 
 
G)      H) 
Figure 6.10b: Drug distribution in terms of concentration (normalized) at slice 1 
of the patient-specific coronary artery wall segment under normal 
condition at E) t = 1 day, F) t = 2 days, G) t = 4 days, and H) t = 7 
days. 
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6.2 DRUG DISTRIBUTION IN A DISEASED ARTERY WALL WITH A VULNERABLE 
PLAQUE 
The diseased artery model contains a vulnerable plaque characterized by a 
large lipid core and a thin fibrous cap, placed in its circumflex branch that is 
roughly 100 mm in length. Vulnerable plaques are more likely to occur close to 
the bifurcation area, which is a recirculation region for blood flow. According to a 
study of ruptured plaques by Jerzy et al. using IVUS in 160 patients, 88% of 
plaques are located within 30 mm of the LAD origin when the average lengths of 
these LADs are within 48±24.8 mm [78]. Based on these observations, the 
idealized vulnerable plaque model was positioned near the branching site. Plaque 
length can be anywhere from 2.0 mm to 50 mm with an average of 26.4 mm [79]. 
The plaque was chosen to be larger than average, approximately 40 mm in length. 
The peak wall thickness (excluding the adventitia) within the plaque is 
approximately 1.1 mm, which agrees with the data in Table 4.1. It can be 
reiterated here that plaque features and dimensions vary over a wide range of 
values depending on the extent of disease and the individual patient. This 
idealized model is just a representative case devised to demonstrate the 
capabilities of the computational toolset developed. The details of this model can 
be found in Figures 6.11 and 6.12. 
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Figure 6.11:  A cut-away view of the diseased patient-specific left coronary artery 
segment with an idealized vulnerable plaque placed in the circumflex 
branch of the LCA. The media is in blue, the intima in green, the 
lipid core in yellow and the thin fibrous cap in red. A cross-section is 
taken along A-A’ midway through the vulnerable plaque 
highlighting the thickening of the intima and lipid accumulation.  
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Figure 6.12: A cut-away view of the diseased patient-specific left coronary artery 
segment with an idealized vulnerable plaque placed in the circumflex 
branch. The media is in blue, the intima in green, the lipid core in 
yellow and the thin fibrous cap in red. A transverse cross-section is 
taken along A-A’ midway through the vulnerable plaque 
highlighting the thickening of the intima and lipid accumulation. 
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In Figure 6.13, the location of the three representative transverse slices are 
presented with slice 1 taken right through the middle of the vulnerable plaque 
located at the circumflex branch of the LCA. Again, due to the closely coupled 
nature of transport between the drug and the nanoparticles, the effect of plaque 
heterogeneity on drug distribution can be better studied by considering the time 
evolution of their distributions together. 
Because of non-uniform wall deposition of nanoparticles (unlike the 
idealized case), a deeper penetration of nanoparticles with a higher concentration 
level at or around the nanoparticle rich wall deposition area was detected. 
Fortunately, the plaque location selected coincides with this dense wall deposition 
site, hence ensuring drug availability to the target region. This may not be the case 
in general. But for the purpose of analysis, this provides an excellent opportunity 
to investigate local transport behavior at the target area when the nanoparticles 
actually marginate preferentially toward the diseased site.  
From Figure 6.14 it appears that the nanoparticle transport behavior 
mimics the corresponding idealized case, that is, slow accumulation and 
entrapment of nanoparticles within the lipid core. This observation is further 
reinforced by the way the nanoparticles gradually seep into the diseased part from 
the surrounding areas, albeit to a lesser extent due to somewhat reduced 
nanoparticle availability in the neighboring healthy part of the artery. The latter is 
a direct consequence of spatial variation of nanoparticle wall deposition.  
The nanoparticle concentration in the lipid pool peaks within 24 hours of 
its administration. This is highly beneficial from an efficiency perspective 
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because this appears to coincide with the initial burst of drug release (see Figure 
4.5). During the first 24 hours drug release rate is steepest by design and close to 
30% percent of the drug becomes available for retention within the lipid core to 
exert therapeutic effect. Beyond this time, the release rate profile flattens out and 
the role of nanoparticles as a source of drug diminishes. 
The drug distribution pattern (see Figure 6.15) essentially follows that of 
the nanoparticles. This is particularly true at early times. However, later on, as the 
nanoparticles overcome the IEL barrier seemingly effortlessly, and then 
eventually clear out through the adventitia and the lumen, the drug remains 
largely confined within the intima. That is, even though the drug is able to 
overcome the lipid core barrier, when it reaches the outer intima, a region of fast 
planar diffusion, the drug gets depleted through the healthy part of the artery into 
the lumen.  Consequently, it appears that the concentration gradient across the 
IEL on the lipid core side does not become steep enough for the drug to diffuse 
through the IEL barrier, which leads to its entrapment within the lipid core.  
Figure 6.16 and Figure 6.17 illustrate the spatial distribution of the 
nanoparticles and the drug at slice 2, respectively, at various times. Comparing 
with Figure 6.9 and Figure 6.10 for the corresponding distributions at slice 1 of 
the healthy patient-specific artery case, it appears that both species exhibit similar 
transport characteristics and pattern of distribution. The difference lies in the 
range of concentration, which can be attributed to the variation in nanoparticle 
wall deposition at these two different slice locations.  
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A side-by-side comparison of the drug distribution for the healthy and 
diseased cases (see Figure 6.18) at slice 2 of the neighboring branch (that is, the 
LAD) reveals that although the time evolution of distribution pattern is essentially 
the same, the healthy branch of the diseased patient-specific artery retains a lower 
concentration of drug compared to its non-diseased counterpart. This implies that 
the lipid core in the vulnerable plaque attracts and accumulates the hydrophobic 
drug from its neighboring healthy branches facilitated by rapid planar diffusion.  
The nanoparticle and drug distribution at various times for slice 3, located 
upstream of the branch with the vulnerable plaque, can be found in Figure 6.19 
and Figure 6.20, respectively. Quite expectedly, the distributions demonstrate 
similar trends to those at slice 2. However, drug concentration is lower at this 
location due to the spatial variation of nanoparticle wall deposition.  
Finally, Figure 6.21 depicts the time evolution of nanoparticle and drug 
distributions side-by-side at a slice taken at 1/3 depth (radially) from the lumen 
side of the patient-specific coronary artery wall segment. These pictures highlight 
the points made above more clearly. For example, they illustrate how the 
hydrophobic drug travels from the healthy parts facilitated by the faster planar 
diffusion and gets trapped within the lipid core of the vulnerable plaque. The 3D 
nature of drug distribution is quite obvious here. 
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Figure 6.13: Schematic of the patient-specific coronary artery model under 
diseased condition characterized by a vulnerable plaque depicting 
the location and orientation of the slices 1, 2 and 3 under 
consideration. Here slice 1 is taken approximately halfway through 




A)     B) 
 
C)     D) 
Figure 6.14a: Distribution of nanoparticles at slice 1 of the patient-specific 
coronary artery wall segment under diseased condition characterized 
by a vulnerable plaque at A) t = 2 mins, B) t = 1 hr, C) t = 6 hrs, and 




E)     F) 
 
G)     H) 
Figure 6.14b: Distribution of nanoparticles at slice 1 of the patient-specific 
coronary artery wall segment under diseased condition characterized 
by a vulnerable plaque at E) t = 1 day, F) t = 2 days, G) t = 4 days, 




A)      B) 
 
Figure 6.15a: Drug distribution in terms of concentration (normalized) at slice 1 
of the patient-specific coronary artery wall segment under diseased 
condition at A) t = 2 mins, B) t = 1 hr, C) t = 6 hrs, and D) t = 12 hrs. 
C)      D) 
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E)      F) 
 
G)      H) 
Figure 6.15b: Drug distribution in terms of concentration (normalized) at slice 1 
of the patient-specific coronary artery wall segment under diseased 




A)      B) 
 
C)       D)  
Figure 6.16a: Distribution of nanoparticles at slice 2 of the patient-specific 
coronary artery wall segment under diseased condition at times A) t 
= 2 mins, B) t = 1 hr C) t = 6 hrs, D) t = 12 hrs. 
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E)      F)  
 
G)      H) 
Figure 6.16b: Distribution of nanoparticles in terms of concentration (normalized) 
at slice 2 of the patient-specific coronary artery wall segment under 
diseased condition at times at times E) t = 1 day, F) t = 2 days, G) t = 
4 days, and H) t = 7 days. 
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A)      B)     
 
C)      D) 
Figure 6.17a: Drug distribution at slice 2 of the patient-specific coronary artery 
wall segment under diseased condition at times A) t = 2 mins, B) t = 
1 hr C) t = 6 hrs, D) t = 12 hrs. 
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E)       F) 
          
G)       H) 
Figure 6.17b: Drug distribution at slice 2 of the patient-specific coronary artery 
wall segment under diseased condition at times E) t = 1 day, F) t = 2 





Figure 6.18a: Distribution of drug at slice 2 of the healthy (left) and diseased 
(right) patient-specific coronary artery wall segment at t = 1 day 





Figure 6.18b: Distribution of drug at slice 2 of the healthy (left) and diseased 
(right) patient-specific coronary artery wall segment at t = 3 days 




A)      B) 
 
C)      D) 
Figure 6.19a: Distribution of nanoparticles in terms of concentration (normalized) 
at slice 3 of the patient-specific coronary artery wall segment under 
diseased condition at times A) t = 2 mins, B) t = 1 hr C) t = 6 hrs, D) 
t = 12 hrs. 
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E)      F) 
 
G)      H) 
Figure 6.19b: Distribution of nanoparticles in terms of concentration (normalized) 
at slice 3 of the patient-specific coronary artery wall segment under 
diseased condition at times E) t = 1 day, F) t = 2 days, G) t = 3 days, 
and H) t = 4 days. 
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A)      B) 
 
C)      D) 
Figure 6.20: Drug distribution in terms of concentration (normalized) at slice 3 of 
the patient-specific coronary artery wall segment under diseased 
condition at times A) t = 2 mins, B) t = 1 hr C) t = 2 hrs, D) t = 3 hrs. 
After 3 hrs only a trace amount of drug can be observed until the 




Figure 6.21a: Nanoparticle (left) and Drug (right) distribution in terms of 
concentration (normalized) at 1/3 depth from the lumen side of the 
patient-specific coronary artery wall segment under diseased 
condition at times t = 2 mins (top) and t = 1 hr (bottom). 
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Figure 6.21b: Nanoparticle (left) and Drug (right) distribution in terms of 
concentration (normalized) at 1/3 depth from the lumen side of the 
patient-specific coronary artery wall segment under diseased 




Figure 6.21c: Nanoparticle (left) and Drug (right) distribution in terms of 
concentration (normalized) at 1/3 depth from the lumen side of the 
patient-specific coronary artery wall segment under diseased 




Figure 6.21d: Nanoparticle (left) and Drug (right) distribution in terms of 
concentration (normalized) at 1/3 depth from the lumen side of the 
patient-specific coronary artery wall segment under diseased 
condition at times t = 4 days (top) and t = 7 days (bottom). 
 138 
CHAPTER 7 
Conclusions and Future Work 
Design and evaluation of local drug delivery systems involve 
understanding the complex interplay between a series of physiological processes, 
along with the physiochemical properties of the compounds delivered and their 
interactions. Concepts and technologies applicable to these configurations have 
been investigated herein in order to realistically simulate physiological 
phenomena and transport forces necessary for device design optimization that is 
otherwise difficult to achieve in an experimental setting.  
In developing such a tool, the biggest challenge lies in the selection of 
parameters that are able to mimic the physiological forces reliably. A number of 
assumptions have been made which are deemed reasonable, however, they should 
be further investigated. The goal was to establish that the computational tool 
developed shows the right trends even though all the parameters may not be 
measurable in a precise way, and therefore is suitable for use in the drug delivery 
business to help optimize drug design parameters. A study of the parametric 
sensitivity of drug transport revealed that both the Peclet number and Damkohler 
number are dominant in the transport process, though it is more sensitive to 
variation in the latter case. The effect of free drug that may be present in the 
formulation in addition to the drug-encapsulated nanoparticles was also explored. 
Although free drug may provide an initial boost to the drug tissue uptake, its 
influence is negligible and limited in scope because free drug penetration is 
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minimal and largely confined to a small area within the intima when the target 
area is usually the media or the plaque (depending on application). Additionally, 
free drug penetration lasts for a few hours at most until it is depleted completely 
through the lumen side boundary. Therefore its residence time may not be 
sufficiently long for it to act as a viable drug source to produce therapeutic effect 
to the surrounding area. Thus inclusion of free drug in the design may not 
augment drug transport effectively. This is an example of how this tool can 
address important design questions. 
The methodology developed was applied to a few cases of physical 
interest in order to demonstrate its capabilities. A few trends were observed that 
make sense intuitively. In the healthy artery case, the nanoparticles have a largely 
uniform distribution within the intima, while there is an appreciable concentration 
gradient within the media during the first 48 hours after their administration. This 
observation agrees well with [39]. The IEL acts as a significant transport barrier 
to both species, though the resistance appears to be more pronounced for the drug, 
as drug transport in the intima is essentially diffusive in nature. This is consistent 
with the findings in [66]. Also, the diseased artery provides more resistance to 
drug transport, as reported in [64]. A comparison of the idealized case with the 
patient-specific one established that due to the highly coupled nature of transport 
between the two species, the nanoparticle wall deposition pattern and its intensity 
have a significant bearing on the overall drug distribution. Another important 
observation is that both arterial inhomogeneity and plaque heterogeneity modulate 
drug transport as expected from [64]. Additionally, drug transport is influenced by 
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drug avidity. A direct consequence is lipid core recruits the hydrophobic drug and 
retains it such that there is a high local drug concentration within this target region 
for a reasonably long period of time. This is encouraging from a therapeutic point 
of view. Furthermore, the time evolution of this local drug distribution within the 
target region is very closely related to the drug release rate profile. Therefore, 
optimal therapeutic effect may be largely dependent on how well the release rate 
profile can be tuned to achieve peak concentration in synchronization with the 
time course of desired biological responses.  
A comparison of the normal versus diseased patient-specific artery wall 
distribution demonstrates that the existence of vulnerable plaque reduces drug 
concentration level in the neighboring healthy branches. This indicates that the 
nanoparticles that are away from the target region may actually contribute to the 
overall therapeutic effect facilitated by the highly anisotropic nature of drug 
diffusion. Observations such as this make patient-specific geometry an essential 
ingredient in simulating realistic transport forces and flow features that are crucial 
for such modeling endeavors. 
The findings of this dissertation provide a research framework for future 
work. An area to be addressed is an extension to non-rigid deformable artery wall 
models by developing a large deformation theory of flow in porous media.  
Incorporation of a bound drug model that will account for the specific and non-
specific interactions of drug with binding sites within the arterial tissue is also 
planned. Furthermore, the modular aspect of this computational tool allows 
incorporation of functionalities fairly easily that can greatly facilitate design and 
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optimization procedures. For example, one can tailor the existing model to 
introduce particle shape factor as a parameter in the coupled mass-transport 
equations. The effects of particle size and shape can be analyzed and validated 
against existing experimental work [80]. Future efforts will also include defining 
metrics (for example, dose homogeneity index, remaining mass percentage, and 




Appendix A: Verification of numerical methods 
Since transport of drug in the arterial wall is a highly diffusion dominant 
phenomenon, it makes pure diffusion a natural candidate for a model test problem 
to evaluate the performance of the numerical methods. The numerical code was 













     in  0 < x < 1, 
C(0,t) = 1,
C(1,t) = 0,
C(x, 0) = 0         on  0 < x < 1 at t = 0,
 (92) 
 
















# . (93) 
Eq. (92) was solved for both the nanoparticles and pure drug with a 
coefficient of diffusion of DI = 1e-12 cm2/s and DII = 1e-9 cm2/s, respectively. 
The simulations were run for a period of 7 days using a time step of 2 minutes. A 
comparison of the numerical results with the analytical solutions in Eq. (93) show 
that the numerical approximations were fairly accurate for the mesh and time step 
chosen. This provided confidence in the accuracy and reliability of the numerical 
methods employed (see Figure A.1). 
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Figure A.1: A comparison of the numerical solution (dot) with the known 
analytical solution (circle) for the nanoparticles (top) and the drug 
(bottom) in 1D under purely diffusive transport as described in Eq. 
(92). Only the interesting part (1/20 of the thickness) of the artery  







MI = Myocardial Infarction 
LDL = Low Density Lipoprotein 
CRP = C-Reactive Protein 
IVUS = Intravascular Ultrasound 
SCD = Sudden Cardiac Death 
NP = Nanoparticle 
MRT = Mean Residence Time 
3D = Three dimensional 
1D = One dimensional 
IEL = Internal Elastic Lamina 
EEL = External Elastic Lamina 
NURBS = Non-Uniform Rational B-Splines 
GMRES = Generalized Minimal Residual Method 
PDE = Partial Differential Equation 
RR = Release Rate 
LCA = Left Coronary Artery 
LAD  = Left Anterior Descending 
MW = Molecular Weight 
kDa = Kilo Daltons 
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HRP = Horseradish Peroxide 
Cp = Centipoise 
















 Diffusivity in the fibrous cap 
 Da = Damkohler Number 
 Pe = Peclet Number 
µm = micrometer 
mm = millimeter 
nm = nanometer 
mins = minutes 
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